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A student once asked: what is the difference between a man of  Tao and a little
man?. The sensei replied: it is simple: when the little man receives his first dan, he can
hardly wait to run home and tell everyone he made his first dan. Upon receiving his
second dan, he will climb to the roof and shout to the people. Upon receiving his
third dan, he will jump in his automobile and parade through town with its horn
blowing, telling everyone about it.
The sensei continued: when the man of  Tao receives his first dan, he will bow his
head in gratitude. Upon receiving his second dan, he will bow his head and his
shoulders. Upon receiving his third dan, he will bow at the waist and quietly walk
alongside the wall so people will not see him or notice him.
First know yourself, then know others
 Gichin Funakoshi (1868-1957)
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Context
History has taught us that vaccines are suitable for controlling many infectious diseases.
The worldwide eradication of smallpox is an example of a successful vaccination
campaign. The level of  other diseases like polio, diphtheria, tetanus, pertussis, and rabies
is significantly reduced by vaccination. But infectious diseases still pose major health
problems, especially in the more impoverished parts of the world and the veterinary
world in which vaccines are too costly or not available [1]. Furthermore, there is much
concern about new and re-emerging infectious diseases in the developed world. The
increased (widespread) use of antibiotics has significantly increased the emergence of
antibiotic-resistant organisms (e.g. Streptococcus pneumoniae, enterococci and gram-negative
enteric pathogens) worldwide [2]. In addition, immunodeficient people and travellers
can be a carrier of  old or foreign infectious diseases. Therefore, development of  vaccines
and vaccination strategies remains important.
Two types of  vaccines can be discerned: live vaccines (composed of  live, attenuated
micro-organisms) and non-living vaccines (composed of inactivated micro-organisms,
subunits thereof, recombinant DNA products or chemically synthesised peptides or
oligosaccharides). Live vaccines possess many of the biological characteristics of the
virulent microorganism like receptor binding, passage through physical barriers and
production of  active components. They are presented via the major histocompatibility
(MHC) class-I-pathway. Although they are highly immunogenic, the microorganisms in
live vaccines have the risk of  return to virulence [1,3]. Obviously, non-living vaccines do
not hold this risk. Since they lack certain characteristics of the alive counterpart, they are
in general less immunogenic and are presented via the MHC class-II-pathway. When
antigens are reduced into peptides, the biological complexity of the original
microorganism is also reduced and this is accompanied by a further loss in immunogenicity.
In the last two decades, considerable scientific progress has been made, which has
revolutionised the way both live and non-living vaccines can be designed, formulated
and produced. Moreover, new immunisation strategies are being explored in order to
simplify the administration of  vaccines.
Mucosal vaccination
Most living pathogens enter the body via the mucosal tissues of the gastrointestinal
(GI), urigenital or respiratory tract. Specific and non-specific defence mechanisms must
limit the consequences. Specific immunity at mucosal tissues is brought about by both
the local (mucosal) and systemic immune system and the first is the most important one
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Box 1.1 The mucosal immune system 
 
 The mucosal immune system (MIS) is stimulated by uptake of antigens (micro-organisms and 
particles) and initiates an immunological cascade that primes the mucosa-associated lymphoid tissue 
(MALT). The MALT represents a compartmentalised, interconnected system of lymphoid tissue with 
various induction and effector sites, like the lamina propria of the upper and lower respiratory tract, 
the intestine, the genitourinary tract, and the salivary, mammary and lacrimal glands [2]. The inductive 
sites of the gut-associated lymphoid tissue (GALT) are the Peyers patches (PP). PPs are found on 
the follicle-associated epithelium (FAE) and are covered with specialised cells called microfold or M-
cells. M-cells sample luminal antigens by receptor-mediated uptake and transcytose them for 
presentation by antigen presenting cells (APC), which are located in the dome-area of the follicle [64]. 
Mucosal epithelial cells express major histocompatibility complex (MHC) class-I molecules and low 
levels of MHC-class II molecules and can also present antigen to CD4+ and CD8+ T-cells [1]. The 
dome area contains mainly B-cells and CD4+ T-cells. The MALT is best primed by local application 
of antigen. Once the mucosal immune system has been triggered, oral boost immunisations induce  
more vigorous responses than parenteral boost immunisations [69].  
 Upon stimulation, primed antigen-specific B- and T-cells migrate via the thoracic duct to the 
draining mesenteric lymphnodes (MLN) and spleen where clonal expansion and isotype-switch takes 
place [65]. The most important effector molecule of the MIS is secreted dimeric immunoglobulin of 
the IgA isotype, sIgA. sIgA is produced in large quantities in both animals and humans (~ 3 g/day in 
human) [66,67], which is more than all other immunoglobulins together [30].  
 Proliferating B- and T-cells enter the circulation and home preferentially to all mucosal effector 
sites and also to peripheral lymphoid organs where, in human, they can differentiate into IgA- and, to 
a lesser extent, IgG-secreting plasma cells [8,13,14]. The interconnection between all mucosal tissues 
is also known as the common mucosal immune system (CMIS) [6,13,65]. The secretion of IgA across 
intestinal mucous membranes is excellently reviewed by MacPherson et al. and Mestecky et al. [67-68].  
 
(box 1.1). Parenteral vaccination induces the systemic immune system, but hardly the
mucosal immune system [4]. Vaccines administered by the mucosal route can induce
both immune systems [2,5-8].
The mucosal tissues represent the interface between the host and its environment and
mucosal vaccines can be applied at any point of the mucosal system. From a practical
point of  view, intranasal and oral vaccinations are most attractive, but intravaginal and
intrarectal vaccinations are considered also (e.g. for protection against HIV [9]). All
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mucosal tissues are connected via the common mucosal immune system (CMIS) (box
1.1). Live mucosal vaccines based on invading microorganisms are able to penetrate the
mucosal tissues due their biological characteristics [10]. Non-living vaccines lack the
feature of passing the physical barrier and are presented by MHC class-II instead of
MHC class-I like live vaccines. Irrespective of  the type of  mucosal vaccine, the major
obstacle in their development is their low and short lasting efficacy [6,11,12].
Oral vaccines
Oral vaccination is the most attractive route of mucosal vaccination because of its
simple way of  administration. In theory, oral vaccines are capable of  inducing both
mucosal and systemic immune responses [13,14]. Progress in the development of oral
vaccines is, however, limited. At present, there are a few commercially oral vaccines
available. In the Netherlands, a polio (OPV, Sabin®) and a typhoid vaccine (Ty21a,
Vivotif  Berna®) are the only prescribed oral vaccines. Both are composed of  live,
attenuated microorganisms. Non-living oral vaccines are still in phase of  research and
development and in the last decade, no major breakthrough has been reported.
Oral immunisation
Besides the nature of the antigen (living/non-living) [12,15], there are several other
factors affecting the outcome of oral immunisation. Factors that may be of influence
in the induction of oral immune responses or oral tolerance instead, are the dose of
antigen, frequency of administration and immunisation protocol, age of first exposure,
immune status of the host towards the specific antigen, species, delivery systems and
use of adjuvants [4]. Non-living oral vaccines preferably must be designed according
to the following criteria: 1) protection of the antigen from enzymatic digestion. Exposure
of the vaccine to low pH and proteolytic enzymes during passage through the GI tract
results in degradation of  the antigen or loss of  conformation [11]; 2) enhancement of
antigen uptake by M-cells or epithelial cells in the GI tract and facilitation of passage
through the epithelial barrier; 3) activation of the innate and/or specific immune system
instead of induction of oral tolerance; 4) induction of immunological memory [16,17].
For a detailed overview of  the pros and cons of  oral vaccines we refer to an excellent
textbook [4] and recent publications [1,2].
Oral tolerance
Oral tolerance is the phenomenon of systemic immunological unresponsiveness that
occurs after oral intake of  antigens. This subject has been recently reviewed by Iijima et
13
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al. [18]. The primary task of the GI tract is absorption of nutrition out of food and
under normal conditions and the body is tolerant against dietary antigens. Immunological
reactions are preferably prevented [7]. Perturbation of the mucosal immune response
may lead to unwanted diseases like food allergy and coeliac disease as a result of
breakdown in oral tolerance [19]. There are several possible mechanisms for the induction
of mucosally induced tolerance. High doses of antigen can induce clonal deletion and
anergy of  T-cells whereas low doses of  antigen can generate regulatory cytokines with
suppressive effects on many aspects of the immune response [2,18-20]. Both mechanisms
lead to suppression of  antigen-specific immune responses. Recently, reports have been
published which revealed possible roles of  γδT-cells, dendritic cells and intestinal epithelial
cells (IECs) in the induction of oral tolerance. The exact mechanisms by which these
cells establish oral tolerance are still under investigation [18,19,21]. Once a T-cell is
tolerised, tolerance can be spread via the cognate interaction between antigen presenting
cells (APC) and/or T-cells. It has been proposed that tolerised cells may mediate their
suppressive effects directly via the production of inhibitory cytokines or indirectly by
competing for growth factors, MHC-peptide complexes, or co-stimulatory molecules
on APC and thus pass on tolerance [19].
For oral vaccination, it is important that the immune system can distinguish the proteins
within a vaccine from common dietary proteins and reacting with an immune response
against the former. When this distinction cannot be made, oral tolerance will be broken
and the immune system will react toward all orally administered antigens.
Mucosal adjuvants and delivery systems
The first obstacle mucosally administered antigens encounter is the non-specific defence
mechanisms along the mucosal surfaces (e.g. cilia in the nasal system, low pH in the
stomach, and proteolytic enzymes in the gut). Then, the antigens have to pass a thick
mucosal layer and the epithelial barrier before they finally reach the immune system.
Microbial pathogens that colonise the host through mucosal surfaces have evolved
strategies to cross these physiological and chemical barriers [12]. Vaccines composed
of  such microorganisms are more successful in surviving the passage through the GI
tract and are efficiently taken up. Live recombinant microorganisms (e.g. Lactobacteria
and Salmonella) can thus be appropriate vectors for oral uptake of various proteins or
peptides [22]. Virus receptor binding of live vaccines with retained ability to invade the
host probably provides a danger signal [23]. This actively stimulates the MIS. In addition,
live vaccines form a constant source of  antigen and can stimulate the MIS constantly.
Non-living vaccines do not have these features and are therefore less successful [10,15,24].
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The immune response can be enhanced by use of appropriate adjuvants and delivery
systems. Until today few mucosal adjuvants are known. Delivery vehicles can protect
oral antigens from degradation and can enhance vaccine uptake. Commonly used delivery
vehicles are microparticles, liposomes, immune stimulating complexes (ISCOMS), and
carrier-molecules, which have been reviewed recently [1,25]. This introduction will only
summarise the main characteristics of  the most thoroughly studied adjuvants.
LT and CT
Escherichia coli heat-labile enterotoxin (LT) and the highly homologous Vibrio cholerae
toxin (CT) are powerful mucosal immunogens and can also act as powerful adjuvants.
Their immunogenicity and adjuvant activity against co-delivered antigens are well
documented [6,26,27]. Orally administered LT and CT predominantly induce T-cell
responses with Th2-associated cytokines (box 1.1), and IgG1 and IgA antibodies.
However, Th1-associated responses like CTL activation are also induced. Both toxins
are composed of two structurally and functionally separate A and B subunits [1].
The toxic A-subunit induces ADP-ribosylation, which causes the disease symptoms
[28,29]. It is highly immunogenic and can act as an adjuvant towards co-administered
antigens. Due to the toxicity, however, LT and CT and their A-subunits are regarded as
too toxic for clinical use. Non-toxic forms with retained mucosal adjuvanticity have
been created by site-directed mutagenesis [30-35]. These mutant toxins demonstrated
that the ADP-ribosylating activity of  LT and CT was not a prerequisite for their adjuvant
effects since enzymatically inactive mutant toxins retain adjuvant activity after intranasal
administration [35].  Nevertheless, ADP-ribosylation appears to enhance the
immunogenic and adjuvant potency of orally administered toxins [33].
The non-toxic B-subunit binds as a pentamer with high affinity to gangliosides (mainly
GM1) [36-38], and induces apoptosis of  CD8+ and CD4+ cells [26]. LTB was taken up
predominantly by the IEC rather than the M-cells [25]. Conjugated to antigens, it can
act as a carrier molecule and induce mucosal and systemic immune responses [26] while
mere mixing with antigen elicits weaker responses [36,39,40]. However, many early
studies on the adjuvanticity of the B-subunits have proven to be inconsistent as the
presence of  traces of  holotoxin could not be excluded. The use of  recombinant LTB
and CTB improved the insight in the adjuvanticity of  the B-subunit [30,41]. Furthermore,
the degree of cross-linking between different conjugate preparations varies, which may
have affected the GM1 binding and decrease the immunogenicity of the conjugate
[42]. Some of these problems can be overcome by genetic constructs, but the fusion
of  genes may also affect the pentamer formation and by consequence the affinity for
GM1.
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It is important to note that coupling of  antigen to LTB or CTB prior to oral delivery
can dramatically decrease the dose required to stimulate tolerance. LTB/CTB then acts
as a carrier that shuttle antigen into a tolerance-inducing pathway associated with the gut
mucosa, but the precise mechanisms are unknown [36]. This other immunological
property of  the B subunit can be used as effective therapy against certain diseases. For
example, oral administration of CTB-insulin conjugates to nonobese diabetic (NOD)
mice could suppress type I diabetes, a model of spontaneous autoimmune disease [12].
This suggests LT and CT have distinct immunological activities and that there is some
sort of  deviation involved that determines the outcome of  oral vaccination: an immune
response or tolerance.
Microparticles
Microparticles are spheres of polymers with diameters ranging from nanometers up
to several micrometers. They may be built from different polymers and are easy to
produce and are stable. Depending on their size, they are taken up by M-cells (box 1.1)
or even epithelial cells [1,43]. When composed of biodegradable and biocompatible
poly (lactide-co-glycolide) (PLG) polymers, microparticles can controllably release
incorporated antigens. Incorporation of  additional immunomodulators or carrier
molecules can improve their potency. There are obvious differences between soluble
and particulate antigens. In general, soluble antigens are less immunogenic and tend to
induce tolerance rather than immune system activation [4]. Particle size is crucial to its
immunogenicity, since small particles are non-specifically taken up by epithelial cells
[43,44].
Liposomes
Liposomes are composed of phospholipids and cholesterol. Antigens can be
incorporated into liposomes, which are stabile in acidic solutions, bile and pancreatin
solutions. Like microparticles, they are actively taken up due to their small size and
particulate formulation. Their efficacy can be improved by adding immunomodulatory
or carrier molecules [1].
ISCOMS
Immunostimulatory fractions of Quillaja saponica (Quil A) have been incorporated
into lipid particles and form immune stimulating complexes (ISCOMS). Hydrophobic
or membrane-associated proteins are able to incorporate spontaneously into the ISCOMS
when present during their assembly. Incorporation of  non-hydrophobic proteins is
more difficult but also possible. ISCOMS are resistant to both temperature and low
16
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Box 1.2 Construction of edible vaccines
There are several ways to accomplish recombinant gene expression in plants: plastid
transformation via particle bombardment (e.g. chloroplast transformation) [70], transient expression
by chimeric plant viruses [56,71,72] and Agrobacterium-mediated transformation [73].
Plastid transformation results in high expression levels of recombinant protein, and due to their
uniparentally maternal inheritance, escape of recombinant genes through pollen can be avoided. It is
appropriate for the production of bacterial antigens but not suitable for the production of
glycoproteins like viral surface antigens, because of differences in glycosylation [73].
Transient expression by transformed plant viruses (e.g. tobaco and cowpea mosaic virus) also
achieves considerable levels of protein. Immunogenic epitopes can be presented on the surface of
plant viruses by making translational fusions within or at the 3 terminus of a coat protein. The
recombinant gene is not passed down to following generations since it is not incorporated into the
plant genome, which takes extra inoculation steps when producing vaccine. The immunogenic
epitopes are expressed in virus-like particles (VLP) or linked to viral proteins [56].
Transformation with Agrobacterium tumefaciens is the most commonly used method although
expression levels obtained with this method are low. The advantage of this method is that foreign
genes are stabile incorporated into the nuclear genome (Figure 1), thus enabling large-scale cloning
and maintenance of selected high-expressing lines and the ability to sexually cross transgenic lines to
obtain multiple proteins expressed in the same plant. One of the major disadvantages of
Agrobacterium-mediated transformation of plants is the low expression level of the recombinant
protein compared to other methods [74].
pH. Their particulate formulation facilitates uptake by M- or epithelial cells. ISCOMS
can induce CTL and are able to stimulate cells of the innate immune system [1,4,45].
Lectins and ligands
Interaction of antigen with mucosal tissues can be improved by binding to lectin-like
structures on IECs. Ligands with affinity for these structures include pili, viral
haemagglutinins, many bacterial toxins, lectins, plant toxins and bacterial invasins. These
ligands can act as carrier (or transport) molecules or as targeting device to antigens. [1].
Direct targeting to M-cells (box 1.1) further enhances antigen uptake. A few interesting
lectins that bind selectively to M-cells have been identified (e.g. Euonymus europaeus in
canine and Ulex europeaus I and II in mice) [46,47]. After binding they are actively taken
up by those cells [47-51]. However, these lectins are species specific and at this moment,
17
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no human M-cell binding lectins are identified. Further studies are involved to prove
their carrier function [52], and, to our best knowledge, successful immunisations have
not been reported yet.
Miscellaneous
In addition to the vehicles described above, the mucosal immune response upon oral
vaccination can be enhanced by adjuvants such as avridine, muramyl dipeptide, saponins
or derivatives thereof [53], aluminum salts [54], or cytokines such as IL-12 possibly in
combination with a suitable delivery system [8]. Ryan et al. gave an excellent overview
of the choice of adjuvant or delivery system and their effect on the polarisation of the
immune response [1]. The immunostimulatory capacities of unmethylated CpG motifs
of bacterial DNA currently receive great attention. CpG oligodeoxynucleotides were
shown to enhance the local and systemic antibody responses to oral, intrarectal or
intranasal immunisation with tetanus toxoid or influenza virus vaccines [1]. CpG motifs
are detected, like bacterial or viral DNA, as a danger signal by the vertebrate immune
system [55].  They cause B-cells to proliferate and secrete immunoglobulin, which directly
synergise with the antigen-specific effects mediated through the B-cell receptor. In
addition, CpGs improve antigen presentation by up regulation of co-stimulatory
molecules and MHC class II molecules [54].
Plants as edible vaccines
The easiest way to deliver oral vaccines is by mixing them with food. This is the basic
concept of  edible vaccines. The increased knowledge on molecular biology made way
for a novel type of  farming, namely molecular farming, which uses ordinary plants as
factories for the production of inexpensive factories for the production of expensive
drugs and vaccines. Production of  vaccines in edible plants or plant parts thereof  gave
rise to a new concept: edible vaccines.
An overview of  the synthesis methods in edible vaccines is given in box 1.2 and
Figure 1.1. Plants have several advantages above traditional productions systems. They
only require simple growth circumstances and large-scale production is easy, which
makes them inexpensive production factories. As with all oral vaccines, administration
of edible vaccines does not require trained personnel and avoids needle-use and its
associated risks [56]. Still, degradation in the stomach and gut is a major concern.
Transgenic plant tissue can possibly act as a natural delivery system by encapsulation of
the vaccine in plant cells with their tough outer wall [3]. Plant tissue may also contain
possible molecules with adjuvant capacities (e.g. Quil A) [57].
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A. tumefaciens-mediated
transformation
Expression 
level assays
Plant regeneration
Immunogenicity
assays
Patatin 
promoter
TerminatorLTB
gene
Targetting
sequence
Targetting
sequence
Insertion in plant 
expression
Callus formation
and selection
NH3- -COOH
Figure 1.1
Construction of an edible vaccine using Agrobacterium tumefaciens mediated
transformation.
Gene transfer into a plant genome is mediated by the plant-infecting bacterium A.
tumefaciens. This bacterium contains a low copy number of a tumour inducing (Ti)
plasmid. The Ti-plasmid transfers part of its DNA (T-DNA) stabile into the plant
genome via a wounded plant cell and the T-DNA. Callus that is formed is allowed to
grow out into mature plants. The LBT-gene is expressed under control of the tuber-
specific promoter patatin. After tuber formation, LTB is expressed and transported
to the endoplasmatic reticulum.
Plants can correctly process and express complex foreign proteins (Table 1.1 and 1.2).
The complex sIgA molecule has been produced successfully in potato and tobacco
plants, including the correct assembly of the two IgA molecules, the J-chain and the
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secretory component [58,59]. Other research groups reported the correct expression
of  pentameric LTB or CTB with GM1 binding activity [60-62].
Choice of plant species and plant part
The ideal edible vaccine should have high protein contents with high expression levels
of the recombinant protein. It should grow fast and should be easy to multiply for
bulk production. Finally, the ideal edible vaccine should not be toxic when given at the
required amounts and should be edible as raw, uncooked food. At this moment, the list
of  food plants that have been transformed is rather long (Table 1.1, 1.2, and 1.3) and
several plants have been tested already for oral immunisation. From this list the most
suitable plant can be chosen from this list.
Bananas are regarded to be ideal vaccine plants as they do not require cooking and
can be grown in developing countries. Growth, however, is slow and the fruit decays
quite rapidly after ripening. Tomatoes grow faster and can be cultivated throughout the
world, but they too decay rapidly. Drying might preserve these foods and overcome
decay [3], but may also alter the vaccine or its bioavailability. Other plausible plants are
maize, carrots, peanuts, rice, wheat, and soybeans [63].
With the availability of  in-depth knowledge on the molecular biology of  potatoes
and its transformation possibilities within our research group, we decided to use this
plant as model. Potato plants can be propagated rapidly from tubers, produced easily
and at large scale, and can be stored for long periods without special precautions [3].
The use of  potatoes has also several drawbacks. Consumption of  raw potatoes might
give complications and cooking may denature the antigens. Being a member of  the
family of solanaceae, they contain several toxic glycoalkaloids of which the highest
levels are found in the foliage, blossoms and sprouts, followed by the peel and the
tuber flesh.
Aim and outline of this thesis
The goal of  the present thesis is to determine the feasibility of  edible vaccines for oral
immunisation. Can edible vaccines provide immunological protection? What
immunisation protocol is most suitable for edible vaccines? Is LTB a suitable adjuvant
for edible vaccines? What are the possibilities of potatoes as vaccine-production system?
For this purpose, the research was focussed on a model with LTB produced in potato
tubers and tested in mice. Protection was determined by measuring systemic and local
antibody responses.
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Table 1.1 Vaccine proteins 
 
Plant 
expression 
system 
Source of the protein Protein/ 
peptide 
expressed 
Transformatio
n method 
Maximum 
expression 
level in 
planta 
Integrity of the 
protein 
Tested 
species 
Immunogenicity and protective 
capacity 
References 
Alfalfa Footh-and-mouth-disease 
virus 
VP1 tobacco mosaic 
virus 
not known  mice immunogenic and protective upon 
injection and oral administration 
Wigdorovitz, 1999 
Arabidopsis Footh-and-mouth-disease 
virus 
VP1 not mentioned not known  ?? immunogenic and protective upon 
injection 
Carillo, 1998 
Arabidopsis Transmissible gastro-
enteritis coronavirus 
Glycoprotein S not mentioned 0.06% TSP  ?? immunogenic upon injection Gomez, 1998 
Lettuce Hepatitis B virus surface protein Agrobacterium < 0.01% FW  mice orally immunogenic Kapusta, 1999 
Lupin Hepatitis B virus surface protein Agrobacterium < 0.01% FW  mice orally immunogenic Kapusta, 1999 
Maize  E. coli LTB not mentioned not known  mice orally immunogenic and protective Streatfield, 2000 
Maize Transmissible gastro-
enteritis coronavirus 
Glycoprotein S not mentioned < 0.01% FW  ?? orally protective Streatfield, 2000 
Potato E. coli LTB Agrobacterium 0.19% TSP GM1-binding 
multimers 
mice, 
human 
orally immunogenic and protective Haq, 1995; Mason 
1998; Tacket, 1998 
Potato Vibrio cholerae CTB Agrobacterium 0.30% TSP GM1-binding ?? orally immunogenic and protective Arakawa, 1997; 
Arakawa, 1998 
Potato Hepatitis B virus surface protein Agrobacterium < 0.01% FW  mice orally immunogenic  Richter, 2001 
Potato Norwalk virus capsid protein Agrobacterium 0.37% TSP VLP form mice orally immunogenic Mason, 1995 
Potato Rabbit hemorrhagic 
disease virus 
VP60 Agrobacterium 0.30% TSP  rabbit immunogenic and protective upon 
injection 
Streatfield, 2001 
Tobacco E. coli LTB chloroplast < 0.01% FW multimers mice orally immunogenic Haq, 1995 
Tobacco Hepatitis B virus Surface protein chloroplast < 0.01% FW VLP form mice immunogenic upon injection Mason, 1992; 
Thanavala, 1995 
Tobacco Norwalk virus capsid protein not mentioned 0.23% TSP intact protein and 
VLP form 
mice orally immunogenic Mason, 1996 
Tobacco Rabies virus Glycoprotein  not mentioned 1% TSP intact protein ?? not known Streatfield, 2001 
Tobacco Transmissible gastro-
enteritis coronavirus 
Glycoprotein S not mentioned 0.20% TSP intact protein >> immunogenic upon injection Streatfield, 2001 
 
Transformed plants that produce vaccine proteins 
(TSP  total soluble protein; FW = fresh weight) 
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Table 1.2 Biopharmaceuticals and plantibodies
Plant expression system Application
Arapdopsis Human enkephalins
Alfalfa Plantibodies
Canola Human hirudin
Maize Human aprotinin
Potato Human lactoferrin
Rice Plantibodies; human interferon-a; human-a-1-antitrypsin
Soybean Plantibodies; human protein C, - somatropin, -erythropoietin, -epidermal growth
factor, -interferon-b, -serum albumin, -hemoglobin a/b, -homotrimeric collagen
Tobacco Angiotensins-converting enzyme, glucocerebrosidase
Tomato Angiotensins-converting enzyme
Wheat Plantibodies
Transformed plants that produce biopharmaceuticals and plantibodies (adapted from Streatfield, 2001).
Table 1.3 Various transformed plants
Miscellaneous plant expression systems
Asparagus Papaya
Banana Pea
Barley Peanut
Cabbage Pepper
Cantaloupe Plum
Carrot Raspberry
Cauliflower Serviceberry
Cranberry Squash
Cucumber Strawberry
Eggplant Sugar beet
Flax Sugarcane
Grape Sunflower
Kiwi Sweet potato
melon Walnut
 Transformed plants with unknown transformation products
(adapted from Richter, 1999)
The first part of the thesis describes the efforts to optimise the immunisation protocol
for transgenic potatoes, and addresses the following questions: can the immune response
be increased by the immunisation schedule? (Chapter 2); can the immune response be
increased by modifying the immune status of the host? (Chapter 3); and is the optimised
immunisation strategy suitable for an antigen produced in potato tuber? (Chapter 4).
Chapter 5 describes the efforts to explore whether LTB-fusion proteins can be produced
in potato tubers and whether LTB was a suitable adjuvant in edible vaccines. The final
chapters of  this thesis discuss the feasibility of  edible vaccines. Are the speculations
about edible vaccines justified? (Chapter 6) and what are the consequences of feeding a
vaccine and are potato tubers suitable vaccine delivery systems?(Chapter 7).
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Summary
Frequent administration of oral immunisation has proven to be more successful than
single administration. The frequency of feeding edible vaccines, however, is limited by
the maximal oral intake, the lack of nutritional value and the possible presence of toxic
ingredients. Therefore, we designed a protocol in which the animals received multiple
immunisations on three alternating days (triple dose) and the protocol was compared
to single immunisations. Mice were immunised via intragastric (IG) gavage with ovalbumin
(OVA) mixed with cholera toxin (CT) and the effects on systemical and local immune
responses were determined. Serum IgG1 and IgA titres against OVA after oral boost
immunisation given three weeks after primary immunisation were significantly higher
after triple dose than after single dose immunisation. Faecal IgA was detected only
after triple dose boost immunisation. A second boost did not further increase serum
IgG1 and faecal IgA. Antibody responses against CT were also elicited and again,
boost immunisations did not further increase this response. We concluded that oral
immunisation with multiple doses was more effective than single dose immunisation
and it seems practical and efficient for edible vaccines.
Introduction
Several factors affect the immune response upon oral administration of antigen and a
few can be manipulated [1]. General complicating factors are degradation of the antigen
in the gastro-intestinal tract and the induction of a state of oral tolerance [2,3].
Furthermore, the nature of  the antigen strongly determines the outcome of  oral
immunisation. Oral administration of live pathogens revealed in many cases significant
mucosal and systemic immune responses [4]. Oral immunisation with non-living
pathogens, subunits or peptides, however, is often inefficient and requires multiple
administrations with large amounts of antigen and adjuvant [5]. Another important
factor is the immunisation schedule. Chalacombe [6] found that a weekly immunisation
did not result in significant responses. Serial immunisations on consecutive days, however,
induced sIgA. These and other data suggested that frequency and timing of  immunisation
are important.
Detailed study on differences between single dose immunisation and multiple dose
immunisation on the development of IgA and IgG1 antibodies and their course in
time after priming and booster immunisation are not described yet. The goal of the
present study was to establish an effective oral immunisation protocol applicable for
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Figure 2.1
Anti-OVA antibody titres after priming and subsequent boost immunisations with 10
mg OVA and 5 µg CT. Arrowheads mark days of immunisation. An asterisk marks
statistically significant differences between single and triple dose oral
immunisations. The data represent GMTs and SEMs of serum IgG1 (A), serum IgA
(B), faeces IgG1 (C) and faeces IgA (D).
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edible vaccines for which the frequency of feeding is limited by the maximal possible
oral intake.
Materials and methods
Mice
Swiss female mice (6 to 8 weeks old) were obtained from Charles River (Sulzfield,
Germany) and housed per groups under conventional conditions. All mice were raised
and kept on an OVA free diet. All animal experiments were held under auspices of  the
ID-Lelystad B.V. Animal Experimentation Committee according to the Dutch Law on
Animal Experimentation.
Antigen preparation and immunisation
The antigen preparation tested consisted of  10 mg of  ovalbumin (OVA; Grade V, A-
5503, Sigma) mixed with 5 µg cholera toxin (CT; C-8052, Sigma) dissolved in 0.4 ml
saline. Mice fasted overnight (water was provided ad libitum) and were immunised orally
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by intragastric intubation with OVA plus CT on day 0, 21, and 42  (single dose) or on
day 0, 2, 4, 21, 23, 25, 42, 44, and 46.
Collection of faeces and serum samples
Pre-immune tail blood serum and faeces samples were collected before the first
immunisation and on day 14, 35, and 49. Fresh faeces pellets were immediately frozen
at 20 °C. Before testing, faeces pellets were treated as described elsewhere to prevent
degradation [7].
Detection of  anti-OVA and anti-CT antibodies
High binding ELISA plates (Greiner, Nürtingen, Germany) were coated overnight at
4°C with 100 µg ml-1 OVA or 2 µg ml-1 CT dissolved in PBS. ELISA was performed
as described earlier [7]. Antibody titres were expressed as the dilution factor of the
sample giving an extinction value of 1 above the background. Geometric mean titres
(GMT) of individual 2-log titres and standard error of the mean (SEM) values were
calculated. Statistical analysis was performed by Students two-tailed t-test. Differences
between groups with P value < 0.05 were considered to be significant. Extinctions
below detection limit were considered to have a GMT of -10.
Results
Antibody responses against OVA
Neither single dose nor triple dose oral priming with OVA plus CT resulted in
detectable anti-OVA immune responses in serum or faeces (Fig. 2.1). Single dose oral
boost immunisations induced anti-OVA IgG1 and IgA titres in serum, and serum IgG1
was significantly higher compared to pre-immune serum on day 28. Triple dose oral
boost immunisations induced significantly higher antibody titres in serum (IgG1 and
IgA) and in faeces (IgA) compared to pre-immune titres. Second boost immunisations
administered on day 42, or at day 42, 44, and 46, further increased serum IgG1 but not
serum IgA or faecal IgA, but only after triple dose boost immunisations. Antibody
titres were significantly higher (IgG1 on day 28 and IgA on day 49) and in faeces (IgA
on day 28) after triple dose immunisation.
The number of responder mice and non-responder mice on day 49 using each
immunisation protocol is represented in Table 2.1. Mice were considered to be
responding when the GMT titre was at least 1. In serum, 4 out of 4 and 5 out of 5
triple dose immunised mice had increased IgG1 and IgA responses, respectively, while
3 out of 5 mice responded with faecal IgA. After single dose immunisation, 4 out of
31
A multiple dose immunisation protocol
Figure 2.2
Anti-CT antibody titres after priming and subsequent boost immunisations with 10
mg OVA and 5 µg CT. Arrowheads mark days of immunisation. An asterisk marks
statistically significant differences between single and triple dose oral
immunisations. The data represent GMTs and SEMs of serum IgG1 (A) and serum
IgA (B).
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5 mice had positive serum IgG1 and 3 out of  5 had positive serum IgA responses.
None responded with faecal IgA. Also, the GMTs on day 49 of  all mice and of  only
the responding mice are represented in this table. Significantly higher GMTs after triple
dose immunisation compared to single dose immunisation are indicated with an a.
Non-responding single dose immunised mice were not responsible for the differences
between the two immunisation protocols.
Antibody responses against CT
Both single dose and triple dose oral priming with OVA plus CT resulted in anti-CT
IgG1 in serum (Fig. 2.2), but serum IgA was observed only after triple dose priming.
Antibody titres were significantly higher after triple dose prime immunisation. Boost
immunisations did not further increase serum IgG1 or IgA and no differences between
the immunisation protocols were found after the boost immunisation. Antibody
responses in faeces were not determined.
Discussion
After oral immunisation with OVA plus CT, OVA-specific IgG1 and IgA could be
measured in serum, and triple dose immunisation revealed significantly higher antibody
titres than single dose immunisation, but differences were not always significant (Fig.
2.1). CT was necessary as adjuvant as OVA without CT did not evoke detectable
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Table 2. 1 Responding and non-responding animals on day 49
all tested mice responding mice
immunisation
protocol
# of responding mice /
# of tested mice n GMT SEM n GMT SEM
serum IgG1 single dose 4/5 5 2.8 3.2 4 6.0 0.6
triple dose 4/4 4 9.0 1.1 4 9.0 1.1
serum IgA single dose 3/5 5 1.0 0.9 3 2.2 0.5
triple dose 5/5 5 5.5 1.1 5 5.5a 1.1
faeces IgA single dose 0/5 5 -1.0 1.3 0
triple dose 3/5 5 3.0a 1.1 3 4.6a 0.8
 The number of responding mice of the total number of tested animals per group is given. Mice were considered to be responding when the antibody titers
was > 1. The GMTs and SEMs of the tested mice (responding and non-responding mice) and of the responding mice are represented. Significantly
differences between triple dose and single dose immunisations are indicated with an a.
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responses (data not shown). Both triple dose and single dose immunisation induced
antibodies to CT, but differences between the protocols were only observed after
prime immunisation.
Triple dose immunisation was able to induce systemic as well as local antigen-specific
antibody responses, whereas single dose immunisation only raised detectable antibodies
in serum. In faeces, OVA-specific IgA but not IgG1 was induced. IgA was the
predominantly produced immunoglobulin by mucosal tissues. Thus, we expected to
find IgA and not IgG1 in faeces. Our results were confirmed by ELISPOT, in which
we observed more IgA than IgG1 antibody secreting cells in the lamina propria
[unpublished results]. But strong mucosal immunogens like CT and CTB are indeed
able to elicit local IgG1 responses [8].
Primary triple dose immunisation was sufficient to induce anti-CT but not anti-OVA
antibodies in serum and faeces. Boost immunisations were necessary to induce detectable
antibody titres. Second boost immunisations further increased anti-OVA serum IgA
titres, but did not further increase serum IgG1 or faeces IgA titres, suggesting that these
latter reached a plateau level. Anti-CT titres already reached a plateau after priming. The
observation of  a plateau suggested that a secondary reaction of  the immune system
towards boost immunisation with an antigen does not occur. This raised the question if
memory is indeed induced in the mucosal immune system. Cebra reported that cells in
the germinal centres of  Peyers Patches (PP) are transient and that successful secretory
IgA responses attenuated the stimulation by secondary mucosal challenge [9]. This might
explain why traditional boost responses were not induced after oral immunisation. Our
findings indicated that memory cells were formed after triple dose priming, but that
the extent of  memory triggering was different for each antibody isotype, each
compartment of the immune system, and the antigen used. CT is more immunogenic
upon oral immunisation compared to OVA and this might explain why differences
between single - and triple dose disappeared after boost immunisations.
Oral boost immunisations were given three and six weeks post-priming. Seven days
after the last booster, all triple dose immunised mice responded with anti-OVA IgG1
and IgA titres in serum, while after single dose immunisation, few animals remain non-
responding. In faeces, 3 out of  5 of  all triple dose immunised mice responded, while
in the single dose immunised group no mice responded. The non-responding animals
were not responsible for the significant differences between single dose and triple
dose immunisation (Table 2.1). Thus, the triple dose immunisation protocol did not
only increase the mean antibody titre, but also increased the number of responding
animals.
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The triple dose oral immunisation protocol as presented in this paper, resulted in
higher antigen-specific antibody titres against non-live antigens than to single dose
immunisation, most probably due to the extended exposure of the antigen to the mucosal
immune system. A major problem in oral immunisation is the degradation of antigen
by the gastrointestinal tract, and prolonged exposure of antigen might give the mucosal
immune system more time to respond. Frequent oral administration can enhance the
efficacy of  edible vaccines. The frequency of  feeding edible vaccines, however, is limited
by the maximal oral intake, the lack of nutritional value and the possible presence of
toxic ingredients. The here proposed triple dose protocol was developed for the use
with transgenic potatoes as edible vaccines [7]. Since potato-produced vaccines contain
less nutrition than standard food and a fasting period is involved, immunisation on
alternating days provides mice 24 hours to recover from immunisation at the disposition
of standard food.
In the study presented here, the antigen dose of each immunisation was equal, which
meant that the triple dose treated mice received a three times higher priming dose than
single dose immunised mice. Future studies must determine whether the antigen dose
can be divided over the three immunisations days to diminish the risk of antigen-
overdose, like toxicity.
Triple dose oral immunisation has been proved to be effective in inducing systemical
and mucosal immune responses and can be applied in feasibility studies with edible
vaccines and to gain more insights in the various aspects of oral immunisation.
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Summary
This paper describes oral boost immunisations of primed animals as an alternative
oral vaccination strategy. Mice were primed orally (PO), intranasally (IN), subcutaneously
(SC), or intraperitoneally (IP) with ovalbumin (OVA) with or without adjuvant. Boost
immunisations were given orally with or without cholera toxin (CT) as adjuvant. Prime
immunisations induced variable IgA and IgG1 titres in serum depending on the route.A subsequent oral boost increased these titres. Use of  an adjuvant in the priming
significantly increased serum IgA and, to a lesser extend, IgG1. Oral boost immunisationinduced significantly higher serum IgA titres in animals primed via the SC, IP and the
IN route compared to the PO route. This was independent of  the use of  CT. Three
oral boosts with OVA plus 5 µg CT given in five days to primed mice revealed higher
IgA titres compared to single oral boosts and anti-OVA IgA titres in faeces were also
detected. Finally, we put together our findings and propose a systemic priming/oral
boost strategy in which mice were primed via the SC route with 100 µg OVA plus 50
µg Butyl16-p(AA), and subsequently orally boosted with three doses of  300 µg OVA
plus 5 µg CT each.
We concluded that oral immunisation is more effective in IN, SC, or IP primed mice
than in PO primed mice, and that the IgA antibody response in serum and faeces can
be improved by increasing the immunisation frequency and the use of appropriate
adjuvants in primary and boost immunisation. The here-formulated strategy improves
the probability of success of oral vaccination. The results are discussed in the light of
the development of  edible vaccines.
Introduction
Oral vaccination is an attractive but not very efficient way to induce immunity. Despite
considerable effort, only few alive oral vaccines are commercially available at this moment.
Several studies demonstrated that oral vaccination requires multiple administrations of
high doses of  antigen, which increases the production costs. Furthermore, oral intake
of  antigen tends to establish a state of  immunotolerance rather than immunity. Obviously,
the primary function of the gastro-intestinal tract is not to develop immunological
reactions to the various food ingredients entering this organ. In order to obtain significant
immune responses, appropriate adjuvants or antigen-delivery systems are used for oral
immunisation [1,2]. The co-administration of antigens with bacterial toxins, such as
cholera toxin (CT) or heat-labile enterotoxin of  Escherichia coli  (LT) improves the immune
response. To deliver non-living antigens to the mucosal immune system, conjugates of
antigen and B-subunits of  CT or LT, or antigens incorporation into microparticles
were used [3-5]. Despite these approaches, oral vaccination with non-living antigen still
induces insufficient levels and duration of immunity [1,2,6,7].
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To improve the efficacy of  oral vaccines and to reduce the risk of  immunotolerance,
we examined the potentials of oral vaccination in mice primed previously by one of
the systemic routes. Several authors have shown previously that oral boost immunisation
of  primed animals is effective in stimulating local and systemic responses. This systemic
prime/oral boost strategy was first reported by Pierce and co-workers in 1977 and
proved to enhance the enteric immune response to non-replication antigens (CT) and
provided long-lasting protection against a subsequent challenge in dogs [8]. The
consequences of  this immunisation strategy on local and systemic immune responses
have been studied further in mice using living antigen [9], OVA [10] and recently using
hepatitis B surface antigen [11]. Furthermore, this immunisation strategy has also been
applied to birds using replicating antigens [12,13]. In our study, we refined this oral
boost concept. Priming conditions such as the type of adjuvant used, route of systemic
immunisation, number of  immunisations, and dose of  antigen were studied. Finally,
we present a systemic prime/oral boost strategy with improved probability of  successful
oral vaccination with non-living antigens.
Materials and methods
Vaccine and adjuvant preparation
Ovalbumin (OVA; A-5503, Grade V, Sigma) was dissolved in saline and mixed with
or without one of the following adjuvants:
rCTB: recombinant CTB [10].
Specol: a water-in-mineral oil-emulsion [10,14].
S/W: squalane-in-water emulsion containing 80 g l-1 squalane and 20 g l-1 Tween 80
[15,16].
SE/S/W: sucrose ester-in-water emulsion containing 8 g l-1 sucrose poly fatty acid, 80 g
l-1 squalane (Merck, Germany), and 20 g l-1 Tween 80 (ICI) in phosphate buffered saline
(Covaccine BV, The Netherlands).
SL-CD/S/W: sulpholipo-cyclodextrin in a squalane-in-water containing 80 g l-1 squalane,
20 g l-1 Tween 80, and 8 g l-1 SL-CD (Fort Dodge Animal Health, The Netherlands)
[16,17].
Butyl16-p(AAA): butyl alkyl-polyacrylate with an esterification grade of 16% (Butyl16-
p(AA)) (Fort Dodge Animal Health, The Netherlands) [18].
CT: cholera toxin (CT; C-8052, Sigma).
Animals
Swiss female mice (6 to 8 weeks old) were obtained from Charles River (Sulzfield,
Germany) and housed per groups under conventional conditions. All animals were
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raised and kept on an OVA free diet. Experimental groups consisted of  five to six
animals. All animal experiments were held under auspices of  the ID-Lelystad BV Animal
Experimentation Committee according to the Dutch Law on Animal Experimentation.
Immunisation and sample collection
All oral immunisations (per orally, (PO)) were preceded by overnight fasting of  mice
(water was provided ad libitum) and administered by intragastric intubation of 0.4 ml or
0.5 ml vaccine. Subcutaneous (SC) and intraperitoneal (IP) immunisations were
administered in a total volume of  0.1 ml. For intranasal (IN) immunisation, the animals
were anaesthetised according to standard methods and 10 µl of vaccine were applied
to each nostril.
Experiment 1: Groups of six mice were immunised by the SC or IP route with 100
µg OVA mixed with or without adjuvant. Three or four weeks later, on day 0, mice
were given PO boost immunisations of  10,000 µg OVA in 0.5 ml saline. Tail blood
serum samples were collected at several time intervals.
Experiment 2: Groups of five mice were immunised by the PO route with 10,000 µg
OVA mixed with 5 µg CT in 0.4 ml saline, or by the IN route with 10,000 µg OVA
mixed with 5 µg CT in the appropriate volume. Others were immunised by the SC or
IP route with 100 µg OVA and 50 µg Butyl16-p(AA) in the appropriate volume. Three
weeks later, on Day 0, all mice were given a PO boost with 10,000 µg OVA mixed with
5 µg CT. Boost immunisations were administered according to a single dose schedule
(day 21) or a triple dose schedule (day 21, 23, and 25) [19]. Tail blood serum and
faeces samples were collected at several time intervals. Fresh faeces pellets were collected
and immediately frozen at 20 °C. To prevent degradation by proteases, faeces samples
were pre-treated as described earlier [20].
Experiment 3: Groups of five mice were immunised by the SC route with 100 µg
OVA and 50 µg Butyl16-p(AA). Three weeks later, on day 0, mice were given a triple
dose PO boost with various doses of  OVA mixed with 5 µg CT. The doses tested
were: 0.01, 0.3, 10, 300, and 10,000 µg. Tail blood serum and faeces samples were
collected at several time intervals and processed as described above.
Detection of  anti-OVA antibodies
High binding ELISA plates (Greiner, Nürtingen, Germany) were coated overnight at
4°C with 100 µg ml-1 OVA (Sigma) dissolved in PBS. Serum and faeces samples were
twofold serially diluted in PBS, 0.05% Tween 20, and 1% bovine serum albumin. ELISA
was performed as described earlier [20].
Statistical analysis
Antibody titres were expressed as the dilution factor of the sample giving an extinction
value of 1 above the background. Geometric mean titres (GMT) of individual 2-log
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Figure 3.1
Serum IgG1 and IgA after prime and oral boost immunisation without adjuvant.One
group of six mice only received an oral boost immunisation (---/PO(-)), other were
SC or IP primed. Serum samples were tested undiluted. The data represent IgG1 (A)
and IgA (B) in serum after priming (day 2, open bars) and oral boost (day 7, filled
bars). The data are shown as GMTs and SD. Statistically significant differences
between naïve and primed animals on day 7 are indicated by an asterisk (P < 0.05).
titres, standard deviation (SD), standard error of the mean (SEM) and antilog (2GMT)
values were calculated. Statistical analysis was performed by Students two-tailed t-test.
Differences between groups with P value < 0.05 were considered to be significant.
Results
Effects of systemic priming with different adjuvants on the IgG1 antibody response in serum after oralboost
Groups of mice were primed by the IP or SC route and three or four weeks later, on
day 0, they were boosted by the PO route. In parallel, groups of naïve mice were
immunised solely by the PO route on day 0. PO boost immunisation of primed but
not naïve mice resulted in high antigen-specific IgG1 responses. Without the use of  anadjuvant for priming, the PO boost increased the serum GMT 5-fold (Fig. 3.1A).
Systemic priming with adjuvant considerably increased the pre-boost IgG1 titre onday 2 (Fig. 3.2A), except with rCTB and S/W. The titre at 7 days post-boost was
considerably increased by PO boosts without adjuvant compared to non-boosted
animals, except after SC priming with Specol.
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Figure 3.2
Serum IgG1 and IgA after priming and oral boost with adjuvants.
The adjuvants rCTB, Specol, Butyl16-p(AA), SE/S/W, S/W, or SL-CD/S/W were
used for the parenteral prime immunisation. Groups of six mice were primed only
(SC(+)/-- or IP(+)/--), or primed and boosted (SC(+)/PO(-) or IP(+)/ PO(-)).
Serum samples were tested undiluted. The data represent IgG1 (A) and IgA (B) in
serum after priming (day 2, open bars) and oral boost (day 7, filled bars). The data
are represented as GMTs and SD. Statistically significant differences between
antibody titres on day 2 and day 7 are indicated by an asterisk (P < 0.05).
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No significant difference between the SC and IP route was observed, except with SL-
CD/S/W, which was more effective after SC administration.
The effect of the PO boost was most pronounced in animals with relatively low pre-
boost titres. The serum titres at 7 days post-boost were significantly higher in animals
primed via the SC or IP route with rCTB, SE/S/W or Butyl16-p(AA), via the SC route
with Specol, and via the IP route with SL-CD/S/W.
Effects of systemic priming with different adjuvants on the IgA antibody response in serum after oral
boost
PO boost immunisation of primed but not naïve mice resulted in detectable antigen-
specific IgA immune responses in serum (Fig. 3.1B). In a few situations, the addition of
an adjuvant to the systemic priming increased the pre-boost IgA titre on day 2 (Fig.
3.2B). Priming via the SC route with SL-CD/S/W or Butyl16-p(AA), or via the IP
route with Specol resulted in significantly increased IgA titres in serum.
PO boosts significantly increased serum IgA titres after priming via the SC or IP route
with SE/S/W or Butyl16-p(AA), via the IP route with rCTB or Specol, and via the SC
route with SL-CD/S/W. No difference between the SC and IP route was observed,
except for Specol, which gave significantly higher IgA titres in serum after IP priming.
Effects of priming route on the antibody response in primed mice
In another experiment, we examined which prime/boost immunisation protocol
resulted in optimal antibody responses. Mice were primed either systemically by the SC
or IP route or mucosally by the IN or PO route on day 21. Butyl16-p(AA) was
selected as adjuvant for systemic priming as it induced significantly enhanced serum
IgG1 and IgA titres after PO boost immunisation. To maximise the mucosal immuneresponse, 5 µg CT was used as adjuvant for the IN and PO immunisations. Three
weeks later, on day 0, PO boosts were given together with 5 µg CT as adjuvant.
The SC, IP, and IN routes were compared to the PO route in their priming efficiency
for an subsequent PO boost immunisation. Pre-boost IgG1 titres in serum were similarafter priming by either route (Fig. 3.3A). Pre-boost IgA titres were significantly higher
after priming via the SC or IN route than after the PO route (Fig. 3.3B). Post-boost
serum IgG1 titres on day 7, post-boost serum IgG1 titres were significantly higher afterIN priming than after PO priming. Post-boost serum IgA titres were significantly higher
after SC, IP or IN priming than after PO priming. SC priming resulted in significant
higher post-boost IgA titres than IP priming. No or very low IgG1 or IgA responseswere detected in faeces (data not shown).
Oral boost of primed mice using a triple dose immunisation schedule
Previously, we demonstrated that three immunisations given in a period of  five days
was more effective than a single dose[19]. In order to improve the efficacy of the oral
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boost immunisation, this so-called triple dose immunisation schedule was applied to
the systemic priming/oral boost protocol. According to this schedule, PO boosts were
administered on three alternating days, i.e. on day 0, 2, and 4. 5 µg CT was used as
adjuvant for the PO immunisations. Compared to a single dose, triple dose PO boosts
enhanced significantly post-boost serum IgG1 titres on day 7 in mice primed by the SCbut not by the PO or IP route. IgA titres were enhanced in all groups boosted with
triple doses (Table 3.1). In faeces, triple dose PO boosts enhanced significantly the IgA
response in all mice, and the IgG1 response in animals primed by the SC but not by theIP or PO route.
Oral boost with graded doses of  OVA
So far, the systemic priming/oral boost protocol consists of SC priming with 100 µg
OVA mixed with 50 µg Butyl16-p(AA) followed by a triple dose boost with 10 mg
OVA mixed with 5 µg CT. To determine the minimal antigen dose for the oral boost,
we have boosted mice with graded doses of  OVA. OVA was administered according
to the triple dose schedule, at doses of 0.01 µg, 0.3 µg, 10 µg, 300 µg or 10,000 µg per
administration mixed with 5 µg CT. Control mice were not immunised. In serum (Fig.
3.4A), significant anti-OVA IgG1 and IgA titres were induced with 300 µg and 10,000µg OVA. Antibody responses in faeces were low, and titres were only significant with
the two highest doses (Fig. 3.4B).
Discussion
The oral vaccines presently available consist of  alive microorganisms. Despite
considerable research efforts, the use of non-living antigens has not resulted in effective
products. Oral administration of  non-living antigens can elicit detectable immune
responses, but these are often low. Apparently, exposure of  the immune system of  the
gastro-intestinal tract to non-living antigens is not a very efficient way to trigger responses.
Here, we examined the efficacy of oral administration of a non-replicating antigen in
systemically (parenterally) primed and naïve animals. The effects of  adjuvants used for
systemic priming, the route of systemic priming, the immunisation schedule, and the
dose of antigen on systemic and local antibody titres have been studied.
Repeated oral immunisation with OVA without adjuvant was not strong enough to
induce detectable immune responses in serum. When oral immunisation was preceded
by systemic immunisation, significant serum responses were detected. IgA was observed
only after the oral boost immunisation. The oral booster increased the IgG1 that was
elicited by the priming. We concluded that systemic administration of  antigen primes
the host for a subsequent contact of antigen with the immune system associated with
the gastro-intestinal tract. This is in agreement with earlier reports demonstrating the
46 Chapter 3
0 2 4 6 8 10 12 14 16 18
IP(+) / PO(+)
SC(+) / PO(+)
IN(+) / PO(+)
PO(+) / PO(+)
GMT
Day -7
Day 7
A
*
0 2 4 6 8
IP(+) / PO(+)
SC(+) / PO(+)
IN(+) / PO(+)
PO(+) / PO(+)
GMT
Day -7
Day 7
B
* * *
*
*
*
Figure 3.3
Serum IgG1 and IgA after priming via different routes and oral boost immunisation.
Prime immunisations were administered via different parenteral (SC and IP) or
mucosal routes (IN and PO) together with an adjuvant. Oral immunisations were
given with 5 µg CT. Serum samples were 40 to 400 times diluted for IgG1
measurement and tested undiluted for IgA measurement. All faeces samples were
tested undiluted.
The results represented are IgG1 (A) and IgA (B) in serum after priming (day 7,
open bars) and oral boost (day 7, filled bars). The data are represented as GMTs ±
SD. Statistically significantly higher antibody titres than in PO(+)/PO(+) primed
mice are indicated by an asterisk (P < 0.05).
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induction of both systemic and mucosal antibody by a combination of systemic and
mucosal immunisation [2,8-10,12,13].
Six different adjuvants, which have been proven to be effective for systemic or mucosal
responses or both, were selected for systemic priming to evaluate whether the immune
response can be further increased. CT and CTB are well-known strong mucosal adjuvants
[3]. Specol is a water-in-mineral oil emulsion with a strong activity towards a wide
range of  antigens. It is similar to Freunds Incomplete Adjuvant, reactogenic and persists
at the site of injection [14,21]. S/W [15,16], SL-CD/S/W and SE/S/W are emulsions
of  squalane-in-water and have considerable adjuvant capacities and low reactogenicity.
SE/S/W and SL-CD/S/W are powerful adjuvants with low reactogenicity upon
systemic immunisation [16,17]. Butyl16-p(AA) is a water-soluble polymer and has been
proved to be effective for both systemic and mucosal immunisation [17,18]. IN
immunisation with Butyl16-p(AA) induced high IgA and IgG responses in the lungs
and spleen. In general and as expected, the adjuvants enhanced pre-boost serum IgG1titres but did not induce detectable IgA responses. Depending on the type of  adjuvant
and route of priming, oral boosts induced IgA responses in serum and further increased
the IgG1 titre. S/W was the only adjuvant that did not enhance pre-boost IgA titres, butthe combination of S/W with the synthetic sulpholipo-derivatives of cyclodextrin (SL-
CD/S/W) or with sulpholipo-derivatives of sucrose (SE/S/W) enhanced significantly
the immune response after SC administration. SE/S/W and Butyl16-p(AA) were the
two adjuvants, which enhanced both IgG1 and IgA titres in pre- and post-boost serum.Applied in oral vaccines, adjuvants might improve the persistence of the antigen in the
gastro-intestinal tract, the targeting of  the antigen to the immune system (e.g. by specific
binding to epithelial cells or facilitating translocation across epithelial surface), or the
molecular context of  the antigen or might activate the immune system (e.g. cytokines)
[4,22]. However, the exact modes of action of adjuvants are still poorly understood.
The effect of  the oral booster was determined on day 7 post-boost. Previous
experiments demonstrated that the post-boost antibody titre was maximal 7 days later
and did not further increase on day 14 or on day 21 (data not shown). The effect of an
oral boost on IgG1 was evident with all adjuvants, except after IP priming with Specol.The increase in antibody titre was most distinct in animals with relatively low pre-boost
IgG1 titres and not, for example, in animals IP primed with Specol. In the latter cases,the systemic priming revealed high titres and the effect of the oral boost was
overshadowed by that of  the prime immunisation. Probably, some kind of  plateau is
reached by strong systemic priming. In addition, mucosal immunisation is not capable
of boosting the immune response to high level, but rather to maintain antibody titres at
a steady level [23]. Oral immunisation mostly induces T-helper type 2 responses, which
was confirmed by our observations that only IgG1 and not IgG2a (data not shown)
was induced. Remarkably, IgG2a was even not induced after systemic priming with an
adjuvant (data not shown). As compared to IgG1, the effects of an oral boost on IgA
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Table 1: Effects of triple dose oral immunisation
serum faeces
IgG1 IgA IgG1 IgA
priming booster Day -7 Day 7 Day -7 Day 7 Day -7 Day 7 Day -7 Day 7
PO(+) PO(+) 7.9 ± 4.3 9.3 ± 3.3 2.9 ± 1.4 3.8 ± 1.5 < 1 < 1 0.3 ± 2.6 0.0 ± 1.2
SC(+) PO(+) 10.3 ± 1.0 12.3 ± 1.3 5.9 ± 0.6 6.7 ± 0.3 < 1 < 1 < 1 < 1
IP(+) PO(+) 10.6 ± 1.2 12.1 ± 0.6 4.9 ± 1.0 5.9 ± 0.1 < 1 < 1 < 1 < 1
3PO(+) 3PO(+) 9.0 ± 1.9 14.1 ± 0.1 3.3 ± 1.1 10.1 ± 1.3a < 1 < 1 < 1 3.4 ± 0.4a
SC(+) 3PO(+) 11.5 ± 0.6 14.8 ± 1.9a 6.0 ± 0.8 9.9 ± 2.2a < 1 1.8 ± 0.8a < 1 6.0 ± 1.3a
IP(+) 3PO(+) 11.0 ± 2.1 15.2 ± 2.3 6.0 ± 1.4 9.0 ± 0.2a < 1 0.1 ± 2.0 < 1 4.9 ± 1.5a
 The data represent the mean 2-log titre ± SD in serum and faeces 7 days before and 7 days after the oral booster. Significantly
higher titres after triple dose immunisation compared to its single dose counterpart
are indicated by an a.
49
Improvement of the systemic prime/oral boost strategy
0
2
4
6
8
10
12
14
16
18
20
0 0.01 0.3 10 300 10,000
Dose of OVA (µg /mouse)
GGMM
TT
IgG1
IgA
A
*
* *
-8
-6
-4
-2
0
2
4
6
8
10
0 0.01 0.3 10 300 10,000
Dose of OVA (µg/mouse)
GGMM
TT
IgG1
IgA
B
*
*
*
Figure 3.4
The relationship between dose of antigen and IgG1 and IgA response.
Mice were primed SC with OVA in various doses and Butyl16-p(AA). Triple dose
oral boost immunisations were given with 5 µg CT. The data represent the post-
boost antibody titres at day 7 in serum (A) and faeces (B) and are depicted against the
antigen dose in milligrams per animal. IgG1 is indicated by squares and IgA by
triangles. Statistically significant anti-OVA titres above the background are indicated
by an asterisk (P < 0.05).
were more obvious and were found with all adjuvants. This was as expected, since
systemic immunisation induces poor IgA responses and the booster immunisations
were given via one of  the mucosal routes. Because IgA is the most important
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immunoglobulin produced by the mucosal immune system, we focussed our study on
this antibody.
Next to the effects of  adjuvants, we studied the effects of  the route of  priming. In
order to maximise the immune response, we decided to use Butyl16-p(AA) as adjuvant
for the systemic immunisation in the further experiments and CT for the mucosal
immunisation. Butyl16-p(AA) was able to stimulate both systemic and mucosal responses
and CT is todays best-known adjuvant for oral immunisation. Systemic (SC and IP)
and mucosal (IN) priming elicited higher post-boost IgG1 and IgA antibody responsesin serum than PO priming, indicating that solely oral immunisation is less effective than
a combination of  different routes. All animals were closely observed during immunisation.
Nevertheless, swallow of the vaccine after IN immunisation could never be completely
excluded. We decided to use the SC route for priming as it is more convenient that IP
and better to control.
In contrast to other findings, no antibodies were found in faeces, despite the use of
CT as mucosal adjuvant [3]. A single oral boost immunisation with OVA is probably
not efficient enough to induce local responses. Manners to further improve mucosal
responses in orally boosted animals were considered. Previously, we observed that
three oral doses in five days revealed higher responses than single doses [19]. This so-
called triple dose immunisation schedule was applied to further increase the effect of
the oral boost. As a consequence of this schedule, the antigen dose is three-fold higher
but also the exposure of the antigen to the immune system is prolonged. Serum and
faeces IgG1 and IgA titres were significantly higher after triple dose immunisation ofnaïve and primed mice than after single dose immunisation. Augmentation of IgA by
oral boost immunisation was detected in serum and faeces. We concluded that significant
local responses can be induced by oral boost immunisation, provided that multiple
doses are given, which is in agreement with observations by others [1]. Besides faeces,
intestinal scrapings were tested and the number of antibody-secreting cells in the lungs
or in the lamina propria of the small intestine were examined (data not shown). No
responses could be detected in these samples. Obviously, these samples could only be
obtained ate the end of the animal experiments which is may probably be not the
optimal time point to measure mucosal immune responses.
The gastro-intestinal tract is originally not designed to react with an immune response
towards orally delivered antigens and multiple oral administrations of antigen harbours
the risk to establish of a state of immunotolerance [26]. The concept of systemic
priming followed by oral boosts prevents the development of oral tolerance. Once the
immune system has established an immunological memory to a certain antigen, tolerance
is not induced by subsequent feeding of the antigen, not even after increasing the antigen
dose and frequency of feeding [27]. Antigen-experienced T cells may be inherently
resistant to induction of tolerance, because these cells are less dependent on co-stimulation
for their activation than naïve T cells. Primed T cells localise in discrete anatomical
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niches where they are capable to sustain their effector functions but are inaccessible for
tolerogenic signals [28]. We only examined the humoral responses by determination of
the number of  antibody-secreting cells in the lamina propria of  the small intestine. We
did not study the number of T cells in serum or any other compartment of the (mucosal)
immune system. These types of studies are of interest in order to elucidate the
mechanisms underlying parenteral priming for oral booster immunisation.
The systemic priming/oral boost strategy is already known for several years [8-
10,12,13,29] . We attempted to further optimise this concept. The highest systemic and
local responses were found after SC priming with 100 µg OVA plus 50 µg Butyl16-
p(AA) as adjuvant, and subsequently triple dose boosted with 300 µg OVA plus 5 µg
CT. Our refined priming/boost strategy may contribute to the development of  more
successful oral vaccines.
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Summary
The efficacy of edible vaccines produced in potato tubers was examined in mice.
Transgenic plants were developed by Agrobacterium tumefaciens-mediated transformation.
The antigen selected was the non-toxic B subunit of the Escherichia coli enterotoxin
(recLTB). A synthetic gene coding for recLTB was made and optimised for expression
in potato tubers and accumulation in the endoplasmic reticulum. Introduction of this
gene under control of the tuber-specific patatin promoter in potato plants resulted in
the production of  functional, i.e. Gm1-binding, recLTB pentamers in tubers. Selected
tubers containing about 13 µg recLTB per g fresh weight were used for immunisation.
Subcutaneous immunisation with an extract of  recLTB tubers yielded high antibody
titres in serum, which were similar to those obtained with bacterial recLTB. The efficacy
of  oral administration of  recLTB tubers was determined by measuring mucosal and
systemic immune responses in naive and primed mice. Animals were primed by
subcutaneous injection of  an extract of  recLTB tuber plus adjuvant. Naive and primed
mice were fed 5 g of  tubers (~ 65 µg recLTB) or were intubated intragastrically with
0.4 ml tuber extract (~ 2 µg recLTB). In naive mice, feeding recLTB tubers or intubation
of  tuber extract did not induce detectable anti-LT antibody titres. In primed animals,
however, oral immunisation resulted in significant anti-LT IgA antibody responses in
serum and faeces. Intragastric intubation of  tuber extract revealed higher responses
than feeding of  tubers.
These results indicate clearly that functional recLTB can be produced in potato tubers,
that this recombinant protein is immunogenic and that oral administration thereof elicits
both systemic and local IgA responses in parentally primed but not in naive animals.
Introduction
Oral vaccination can lead to protection against infectious agents entering the body via
mucosal surfaces of the host [1-3]. Oral vaccines have the advantage of being safe and
easy to administer but exploitation is hampered by low efficacy, induction of
immunotolerance rather than an immune response, proteolytic degradation of the
antigens during passage through the gastro-intestinal tract and exposure to extremely
acidic conditions in the stomach [4]. Naturally stable and encapsulated antigens may
survive the harsh environment of  the gastro-intestinal tract. At present, heat-labile
enterotoxin of  Escherichia coli (LT), its homologue Vibrio cholerae toxin (CT) and their B-
subunits are among the very few effective, nonliving mucosal immunogens known.
The relatively strong immunogenicity after local administration might be related to the
intrinsic mucosal adjuvant activity of these components [5]. The mechanisms underlying
the mucosal immunogenicity of these substances are still not precisely known [6].
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The widespread use of  these antigens requires large-scale fermentation and purification.
In principle, plants, especially edible plants or parts thereof, are simple production
systems, as they do not require complicated production facilities and purification
procedures [7]. It has been shown that recombinant multimers of  B-subunits of  LT
and CT can be produced successfully in potato and that they are immunogenic upon
oral intake in animals [8-10] and humans [11]. In these studies, oral application resulted
in significant levels of protection against a challenge with the respective toxin [10,11].
Recombinant CT-B in potato tuber is stable upon cooking and preserved its biologic
activity including its ability to bind to Gm1 [9]. This suggested that the tuber matrix
might provide some degree of protection of the antigens against rapid degradation.
Here we report the expression of  functional recLTB in tubers of  transgenic potato
plants and the capability of  tuber-derived recLTB to evoke mucosal and systemic
antibody responses in mice. Effects of  oral immunisation with recLTB tubers were
examined in both naive and primed animals. For this purpose, mice were primed by
subcutaneous injection of  an extract of  recLTB tubers plus adjuvant. The adjuvant
chosen for parenteral injection was a synthetic polymer of polyacrylate modified
chemically with butyl esters (butyl16-p(AA)). This adjuvant has been shown to be a
strong mucosal adjuvant for intranasal immunisation [12].
Materials and Methods
Design of  LTB plant expression cassette
For expression in potato tubers, a synthetic gene for LTB (synLTB) was prepared based
on the sequence of  pYA3047 [13]. At the 3-end a nucleotide sequence was added coding
for the hexapeptide Ser-Gln-Lys-Asn-Gln-Leu (SEKDEL) for retention of the protein in
the endoplasmic reticulum. Unique restriction sites were introduced in the flanking and coding
regions of  synLTB at intervals. Putative polyadenylation stop and mRNA instability motifs
were removed and codon usage was altered in favour of  use in solanaceous crops. SynLTB
was made by ligation of fragments each obtained upon enzymatic conversion of two
synthetic complementary oligonucleotides with overlapping 3-ends as described previously
[14]. The resulting gene was placed under control of the class I patatin promoter [15] and
nopaline synthase terminator (Tnos) sequence and cloned in the binary vector pBINPLUS
[16] generating pLANTIGEN4 (Figure 4.1). As a control, an empty expression cassette
comprising the patatin promoter and nopaline synthase terminator sequence was cloned in
pBINPLUS generating pBINPLUSPAT.
Potato transformation and production
pBINPLUSPAT and pLANTIGEN4 were introduced in Agrobacterium tumefaciens strain
Agl0 [17] by electroporation and used for transformation of  Solanum tuberosum cultivar
Désirée (De Z.P.C., Leeuwarden, The Netherlands) essentially as described by Stiekema et al
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Figure 4.1
Schematic representation of the binary vector pLANTIGEN4 containing the
synthetic gene for LT-B. RB, right T-DNA border sequence; Tnos, nopaline
synthase terminator; SynLT-B, synthetic gene construct coding for LT-B; nptII,
neomycin phosphotransferase II gene, plant selectable kanamycin resistance marker;
Pnos, nopaline synthase promoter; LB, left T-DNA border sequence; nptIII,
neomycin phosphotransferase III gene, bacterial selectable kanamycin resistance
marker; CoIE1 and RK2, origins of replication.
[18]. Shoots were rooted on MS20 supplemented with 0.05 mg.l-1 indole acetic acid (Duchefa),
7 g.l-1 purified agar, 100 mg.l-1 kanamycin, 250 mg.l-1 cefotaxim and 250 mg.l-1 vancomycin.
For bulk tuber production, selected transgenic plants were multiplied in vitro by cutting. All
experiments with transgenic plants were performed under the auspices of  the Dutch
Committee for Genetically Modified Organisms (COGEM) according to the Dutch law
and European guidelines 90/219/EC and 90/220/EC.
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Preparation of tuber extracts and protein analysis
Skinless tuber was extracted in 25 mM sodium phosphate pH 6.6, 100 mM NaCl, 1
mM ethylenediamine tetraacetic acid, 50 mM sodium ascorbate, 1% Triton X-100 and
20 mM sodium metabisulphite. Tissue homogenate was centrifuged at 4°C, 12000 rpm
for 5 min and supernatant was collected and transferred to a fresh tube. Total soluble
protein was estimated by the method of  Bradford. For subcutaneous and intragastric
immunisation, the supernatant was dialysed extensively (MWCO 10.000 Da), and freeze-
dryed. Proteins were re-suspended in small volumes of de-ionised water for
immunisation purposes. Ganglioside GM1 ELISA was performed as described [19]
with 5 µg ml-1 Gm1(Sigma, St. Louis, MO). Fixed amounts of total soluble tuber
protein were loaded onto the plates. As a standard, control tuber extract was spiked
with twofold serial dilutions of  bacterial recLTB (kindly provided by Dr. L. de Haan,
Groningen).
Immunisation of mice
Female Swiss mice (6 to 8 weeks old) were obtained from Charles River (Sulzfield,
Germany) and housed under D2 conditions. Experimental groups consisted of  five
animals. All animal experiments were held under auspices of  the ID-Lelystad B.V. Animal
Experimentation Committee according to the Dutch Law on Animal Experimentation.
To evaluate immunogenicity, mice were subcutaneously immunised on day 0 with 0.1
ml extract from recLTB tuber or with 0.1 ml bacterial recLTB. As adjuvant, 50 µg ml-
1 butyl16-p(AA)13 dissolved in PBS was used. To evaluate immunogenicity upon oral
administration, some groups of naive mice were immunised orally with tuber-derived
recLTB on day 0, 2, and 4, a so-called triple-dose schedule. Oral immunisations were
administered by feeding 5 gram of non-peeled, sliced tuber for 24 hours, or by
intragastric intubation with 0.4 ml tuber extract. Before oral immunisation, mice fasted
overnight while water was provided ad libitum. Other groups of mice were primed
subcutaneously with 0.1 ml tuber-derived recLTB mixed with 50 µg ml-1 butyl16-p(AA)
on day 0. Booster immunisations were given orally 3 weeks later, at day 21, 23, and 25.
Mice were sacrificed at day 42. Control animals were immunised orally with control
tubers (pBINPLUSPAT).
Serum samples were collected at several time intervals from tail blood. Four to six
fresh faeces pellets were collected and immediately frozen at 20°C. Before analysis,
faeces pellets were dissolved in 750 µl protease inhibitor solution (2 mM phenylmethyl
sulfonyl fluoride in isopropanol, 44 mg ml-1 bovine serum albumin, 0.002 mg ml-1
trypsine inhibitor, 1 mM ethylenediamine tetraacetic acid (all from Sigma), and 0.002
mg ml-1 sodium azide (Merck)).
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Figure 4.2
RecLT-B expression levels in transgenic potato tubes. Production of recLT-B in
tubers of 16 independent transgenic recLT-B plants numbered arbitrarily and one
control plant (PAT) was analysed by Gm1-ELISA and expressed in µg g-1 FW. Mean
values and standard deviations of three independent analysis are represented.
Detection limit is < 13 nmole kg-1.
Antibody determination in serum and faeces by ELISA
ELISA plates (Greiner, Nürtingen, Germany) were coated overnight at 4°C with 0.1
µg.µl-1 LT (Sigma) dissolved in PBS. Serum and faeces samples were twofold serial
diluted and antibody subclasses were detected with biotin-labelled goat anti-mouse
IgG1 and IgA (diluted 1/2000, Zymed, San Francisco, CA) and horseradish peroxidase-labelled streptavidin (diluted 1/2000; DAKO A/S, Glostrup, Denmark) was used for
detection. As the substrate, 0.1 mg.ml-1 tetramethylbenzidine and 0.005 v/v% H2O2was used. Extinctions were measured at 450 nm. Antibody titres were calculated as the
dilution of the sample giving an extinction value of 1 above the background. Geometric
mean titres (GMT) of individual 2-log titres, SEM and antilog (2GMT) values were
calculated. Statistical analysis was performed by the two-side Students t-test. Differences
between groups with P values > 0.05 were considered not to be significant.
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Table 4.1 Anti-LT IgG1 responses in serum after subcutaneous immunisation with potato recLTB or with bacterial
recLTB.
2-log anti-LT IgG1 antibody titre in serum at:
Antigen day 0 day 14
GMT SEM antilog GMT SEM antilog
tuber recLTB 6.1 1.7 71 13.9 0.5 14766
bacterial recLTB 8.0 0.6 249 15.1* 0.6 35610
Groups of 5 mice were immunised subcutaneously and antibody titres against LT in serum were measured by ELISA. The mean of 2-log antibody titres
(GMT), SEM and antilog values were calculated.
*Significantly different (P < 0.05).
Results
Genetic modification of potato
pLANTIGEN4 was introduced in Agrobacterium tumefaciens and used in transformation
experiments. Transformation of  internodes of  cultivar Désirée finally generated 22
independent transgenic plants containing the pLANTIGEN4 gene construct (Figure
4.1). As a control, pBINPLUSPAT was used in transformation experiments, comprising
the binary vector with an empty patatin class I promoter cassette. Tubers were harvested
after 2 to 4 months from 16 out of the 22 pLANTIGEN4 transgenic plants and from
one pBINPLUSPAT plant.
recLTB production
Analysis of  tuber material spiked with bacterial recLTB revealed that 25 pg recLTB
per µg water-soluble tuber protein could still be measured in the Gm1-ELISA. Most
of  the tubers contained GM1-binding recLTB and this could be detected using a LTB5specific monoclonal antibody (Figure 4.2). The concentration of  recLTB was calculated
based on an estimated protein content of 7 mg g-1 fresh weight (FW) tuber as was
measured for the potato cultivar that was used (data not shown). Maximal concentration
of  recLTB was 17 µg recLTB per g tuber corresponding with 1.3 µmoles kg -1
monomeric recLTB and 0.26 µmoles kg 1 pentameric recLTB.
Immunogenicity of  tuber-derived recLTB
To determine immunogenicity of  tuber-derived recLTB, mice were immunised
subcutaneously with a tuber extract containing 45 µg recLTB or with 45 µg bacterial
recLTB. Serum samples were collected at days 0 and 14. Both recLTB proteins elicited
significant anti-LT antibody responses in serum (Table 4.1). At day 14, the 2-log antibody
titre in serum was 13.9 and 15.1 for tuber recLTB and bacterial LTB, respectively. This
indicates that plant recLTB is comparably immunogenic as the bacterial LTB.
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Figure 4.3
Anti-LT IgG1 responses in serum after oral immunisation of naive and primed mice.
Antibody titres were determined by ELISA at different time intervals after oral
immunisation of naive mice (open figures) and subcutaneously primed animals (filled
figures) with recLT-B tubers (circles), extract of recLT-B tubers (squares) or control
tubers (triangles). Arrowheads mark time of immunisation.
Oral immunisation of  naive mice with recLTB
Groups of  mice were fed 5 g of  sliced, non-peeled tubers containing ~ 65 µg recLTB
or 5 g control tubers. Tubers were swallowed completely within 24 hours leaving only
the tuber skin. Other groups of mice were intragastrically immunised with 0.4 ml tuber
extract containing ~ 2 µg recLTB. Mice fed with control tuber did not develop significant
antigen-specific antibody titres. Neither IgG1 nor IgA antibodies against LT were detected
in serum and in faeces after administration of  recLTB tubers or tuber extract (Figures
4.3 to 4.5).
Oral booster of  primed mice with recLTB
Groups of  mice were primed subcutaneously with ~ 0.5 µg recLTB in tuber extract
mixed with the adjuvant butyl16-p(AA). Oral booster immunisations were given 3
weeks later using ~ 65 µg recLTB in tuber or ~ 2 µg recLTB in tuber extract. Two
weeks after s.c. priming, IgG1 antibody titres were detectable in serum and antilog
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Figure 4.4
Anti-LT IgA responses in serum after oral immunisation of naive and primed mice.
Antibody titres were determined by ELISA at different time intervals after oral
immunisation of naive mice (open figures) and subcutaneously primed animals (filled
figures) with recLT-B tubers (circles), extract of recLT-B tubers (squares) or control
tubers (triangles). Arrowheads mark time of immunisation. Statistically significant
values are indicated by an astrix.
values ranged from 10 to 23 (Figure 4.3). No IgA was found in serum or in faeces
(Figure 4.4 and 4.5). When no booster immunisation was given, serum IgG1 and IgA
titres at day 29 and 42 remained at the level of day 15 (filled triangle).
An oral boost after subcutaneous priming increased serum IgG1 titres but the
differences with primed but non-boosted animals, were not statistically significant (Figure
4.3). After oral booster immunisations, serum IgA antibody titres were significantly
enhanced at day 29 and 42 as compared to titres in primed but non-boosted animals
(Figure 4.4). Intragastric immunisation with tuber extract generated higher IgA responses
than feeding tubers though these differences were not statistically significant.
In faeces, a small but significant increase in IgA titre was detected after intragastric
booster immunisation with tuber extract but not after feeding with tubers (Figure 4.5).
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Discussion
Plants are recognised as safe and cheap production system for proteins of
pharmaceutical interest including vaccines [20,21]. In the past few years, recombinant
plants expressing antigens or antibodies have been developed successfully by using
plant viruses or Agrobacterium tumefaciens-mediated transformation [22,23]. We examined
the production of  recLTB in potato tubers and the applicability of  these tubers for oral
immunisation. In order to obtain sufficient production levels of this bacterial protein in
transgenic plants, a synthetic gene was made for retention in the endoplasmic reticulum.
Introduction of this synthetic gene in potato under control of a tuber-specific promoter
yielded several independent transgenic lines. Most of  these lines produced LTB pentamers
as became apparent from tissue blotting (data not shown), Gm1-ELISA and Western
analysis under non-reducing conditions (data not shown) using a LTB5 specific monoclonalantibody. As compared to bacterial recLTB, a slightly lower migration rate of  tuber
recLTB was observed suggesting a slightly higher molecular weight (data not shown).
This difference might be the consequence of the addition of the flexible linker and the
ER-retention signal at the extreme carboxyterminus. About half  of  the transgenic plants
produced Gm1-binding recLTB at levels of  10 µg up to 17 µg per gram fresh weight
(FW). Modification of the coding sequence greatly affects expression levels [10,24]. It
was reported that the incorporation of ER-retention signal can augment expression
levels of  recLTB [25] but our data do not support this observation. However, the
production levels measured in our transgenic plants underestimate the real values as
recovery of  recLTB from tuber material is not complete (data not shown). In addition,
quantitative analysis of  recLTB by the Gm1-ELISA is affected negatively by tuber
material  such that the sensitivity is reduced dramatically and in a dose-dependent fashion
(data not shown).
Subcutaneous immunisation of  extract of  recLTB tuber elicited high anti-LT antibody
titres in mice. This indicated that the tuber-derived recLTB is immunogenic (Table 4.1).
However, oral immunisation of  naive mice by feeding recLTB tubers or by intragastric
intubation of  recLTB tuber extracts did not evoke detectable IgG1 or IgA antibody
titres in serum. In addition, these animals were not protected against a challenge with
LT (data not shown). Possible explanations for the absence of  anti-LT responses in our
studies include an inadequate immunisation schedule, too low doses of antigen, too
low immunogenicity of  the tuber recLTB, too low sensitivity of  the detection system
and interference of tuber material with the development of an immune response. Using
our triple-dose schedule, the total amount of  recLTB antigen administered by intragastric
intubation and feeding was 6 and 200 µg per immunisation per animal, respectively. An
increase of the number of immunisations from two to four series of triple oral feedings
with 5 g recLTB tubers per immunisation and a total dose of  780 µg recLTB per
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Figure 4.5
Anti-LT IgA responses in faeces after oral immunisation of naive and primed mice.
Antibody titres were determined by ELISA at different time intervals after oral
immunisation of naive mice (open figures) and subcutaneously primed animals (filled
figures) with recLT-B tubers (circles), extract of recLT-B tubers (squares) or control
tubers (triangles). Arrowheads mark time of immunisation. Statistically significant
values are indicated by an astrix.
mouse, also did not result in detectable IgG1 or IgA titres in serum or faeces. Other
investigators reported LTB-specific antibody responses in serum and mucosal secretions
after oral immunisation of mice by intubation of leaves of transgenic plants expressing
Escherichia coli LTB at comparable doses [24].  Similar experiments with potato tubers
containing recLTB or its homologue recCT-B resulted in antibody responses in mice
and humans and protection against a challenge with the respective toxin [9-11].
Furthermore, we measured antibody titres against the holotoxin LT and not against
LTB, which was the antigen, used for immunisation. It can not be excluded that a large
portion of  antibodies generated by tuber recLTB are unable to bind to LT due to
difference in structure [26] or to the inaccessibility of  antigenic determinants.
As a consequence of the lack of responses, we examined other possibilities for oral
immunisation. Previously, it was reported that intraperitoneal injection of  mice with
antigen primed for subsequent oral booster immunisation as shown by increased intestinal
as well as systemic immune responses [27]. This phenomenon of oral boosting of
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primed animals is not exclusive for the intraperitoneal route of immunisation, the antigen
tested or the adjuvant used. In the study presented, we compared the effects of oral
immunisation of  subcutaneously primed mice with that of  naive animals. The primary
subcutaneous immunisation induced IgG1 responses in serum whereas IgA responses
in both serum and faeces remained low. Subsequent oral immunisation augmented
significantly the humoral response in primed but not in naive animals. In the primed
mice, IgA antibody titres in serum and faeces were augmented significantly while the
IgG1 titre in serum remained unaltered. Apparently, once the immune system is primed,
oral immunisations are capable of boosting the IgA but not the IgG1 response. The
lack of  effect on serum IgG1 suggests that the response to the oral booster immunisation
is induced and developed at the mucosal site. The mechanisms underlying the increased
responsiveness of parenterally primed animals to orally delivered antigens are not clear
yet. It is known that lymphocytes can migrate from spleen and circulation to mucosal
tissues, where they can proliferate and produce IgA upon encountering antigens entering
the body via a mucosal route [28]. Explanations for the immune response to orally
administered antigens in parenterally primed animals include improved absorption or
uptake of antigens by the gut, altered antigen processing favouring immunoresponsiveness
rather than immunotolerance, enhanced capability of the primed immune system to
react to small quantities of  antigen entering the body, etc. Further research is needed to
elucidate the processes involved. This concept of the oral boost is of great interest to
the development of oral vaccines as it may render detectable responses in situations
where normally no immune response would occur.
There was an obvious difference between feeding tubers and the intubation of tuber
extracts. Despite the 30-fold higher antigen dose, feeding tubers was significantly less
effective than intubation in inducing IgA in primed animals. This might be due to the
method of  administration or the antigen preparation. Experiments performed previously
by our group demonstrated that oral immunisation by feeding standard food
supplemented with antigen is less effective in inducing local and systemic immune
responses than intragastric intubation of the same dose of that antigen [29]. This difference
indicates that protein degradation in the gastro-intestinal tract is an important factor.
These observations implicate that studies on intragastric intubation are limited indicative
for the efficacy of edible vaccines and overestimate the potentials of oral vaccines
produced in plants.
In conclusion, we demonstrated that potato tubers might be a potential source
of oral vaccines for direct application and that they can produce considerable levels of
functional recLTB pentamers. Transgenic tubers induce specific immune responses
depending on the route of administration and immune status of the animal. In our
hands, oral immunisation solely by feeding transgenic tubers was not effective. Activation
of the immune system by a primary immunisation via a parenteral route followed by
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booster via the oral route resulted in significant systemic and local responses. The
administration of edible vaccines in primed instead of naïve subjects reveals a more
sensitive test system and higher probability of  success. Further research is required to
optimise this approach and to identify the underlying mechanisms.
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Summary
Two types of  transgenic potato plants were developed expressing the B-subunit of
heat-labile enterotoxin of  Escherichia coli  (LTB) together with a glycoprotein (E2) of
Classical Swine Fever virus: 1) E2 co-expressed with LTB (E2 + LTB) and 2) E2
genetically conjugated to LTB (E2-LTB. Subcutaneous (SC) immunisation of  extracts
of  these E2 + tubers induced significant serum antibody titres against LT indicating that
these constructs were immunogenic. Oral immunisation of naive mice with these tubers
or tuber extracts did not result in detectable serum responses. In addition, serum antibody
responses in SC primed mice were not enhanced by oral booster immunisations. At
mucosal level, feeding of  E2 + LTB tubers elicited significant IgA responses in intestinal
scrapings against LT but not against E2.
We concluded that LTB-fusion proteins expressed in potato plants are immunogenic
and that oral administration mostly evoked low IgA responses at local level but not in
serum and only in SC primed animals. LTB did not increase the response against fused
or co-administered E2. Our results are discussed in the light of feasibility of edible
vaccines.
Introduction
Oral vaccination is regarded to be an attractive alternative for injected vaccines as it is
easy to apply, cheap and safe. Furthermore, it can induce protection at mucosal level, at
the site of entrance of many pathogens and it enables mass vaccination via food or
drinking water. However, oral vaccination is often not very effective. The immune
response is short lasting and large doses of antigen are needed, even when alive
microorganisms are used [1-3]. Strong mucosal adjuvants and antigen-presentation
systems are needed, especially for non-living antigens. Until today, the only known strong
mucosal immunogens are the heat-labile toxin of  Escherichia coli (LT) and cholera toxin
of Vibrio cholerae (CT) and their A and B subunits which might be related to their
intrinsic adjuvant activity. These toxins are interesting candidates for edible vaccines as
they can be expressed in plants such as tobacco [4], maize [5] and potato [4,6-10] and
retained their biological activity (i.e. GM1-binding) even after boiling [9]. Feeding of
transgenic potato tubers to mice [7] and humans [8] resulted in the induction of specific
antibodies in serum and faeces. The antibody titres were often low but still high enough
to confer protection against a challenge with the toxin [7]. Despite considerable variation
in expression levels between individual plants and plant tissue parts and the low immune
responses upon oral intake, edible vaccines are believed to be promising. Oral vaccination
of  primed but not naive mice with LTB tubers induced serum and local IgA [6].
Here we examined whether LTB produced in plants is capable of  enhancing the
immune response against co-expressed of  genetically fused antigens. LTB is the non-
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toxic part of  LT and the adjuvant function depends on the pentameric conformation
and is most pronounced when conjugated chemically to the antigen. We describe the
production and testing of a fusion protein in Solanum tuberosum Desiree tubers namely
the fusion protein of  LTB and a glycoprotein of  classical swine fever (E2) [11].
Furthermore, LTB and E2 co-expressed as separate molecules in one single potato
plant is examined. The immune responses against these antigens after feeding with
tubers and oral administration of tuber extracts are compared.
Materials and methods
Potato tuber-derived vaccines
For immunisation experiments tubers from four different selected transgenic potato
lines were used: PAT, pL421, pL1317 and pL4+14#109. Control plants (PAT) and
potato plants accumulating LTB pentamers in tubers (pL421) have been described
before [6]. The expression level of  LTB in pL421 tubers approximates 15 µg pentamers
per gram fresh weight (FW). pL1317 harbours a gene construct coding for a fusion
protein consisting of  LTB and the classical swine fever virus (CSFV) E2 glycoprotein as
present in the pRb2 vector described before [6]. The expression level of  LTB-E2
fusion protein in tubers of  pL1317 approximates 0.1 µg pentamers per gram FW.
pL4+14#109 harbours the expression cassette giving rise to accumulation of  LTB
pentamers in tubers similar to that of pL421 in conjunction with an expression cassette
giving rise to accumulation of the CSFV E2 glycoprotein. pL4+14#109 tubers hence
accumulate both LTB and CSFV E2 in one cell. The expression level of  LTB in these
tubers approximates 10 µg per gram FW and that of CSFV E2 approximates 1 µg per
gram FW.
Immunisation of mice
For subcutaneous and intragastric immunisation, large scale extracts were made as
described before [6] from 300 g of  tubers of  pL1317 (LTB-E2), PAT (control tubers)
and 600 g of  tubers from pL4+14#109 (E2 + LTB). Supernatants harbouring the
vaccines were dialysed once against excessive extraction buffer and six times against
excessive de-ionised water for 48 h using SnakeSkin pleated dialysis tubing (Pierce
Chemical Company, Rockford, USA; MWCO 10 kDa) and concentrated by freeze-
drying and subsequently re-suspended in small volumes of de-ionised water for
immunisation purposes. The final concentration of  the vaccines was determined by
Gm1-ELISA or Western blotting as described. For oral immunisations using tubers,
these were peeled and sliced prior to oral immunisations.
Female Swiss mice (6-8 weeks old) were obtained from Charles River (Sulzfield,
Germany) and housed under D2 conditions. Experimental groups consisted of  five
animals. All animal experiments were held under the auspices of  the ID-Lelystad B.V.
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Animal Experimentation Committee according to the Dutch Law on Animal
Experimentation. Oral immunisations were administered on three alternating day, a so-
called triple dose schedule [12] by feeding 5 g peeled and sliced tuber for 24 h, or by
intragastric  (IG) administration with 0.4 ml of tuber extract. Before oral immunisation,
mice were fasted overnight while water was provided ad libitum. Naive mice were orally
immunised on day 0, 2, and 4 and were given boost immunisations on day 21, 23, and
25. Other groups of mice were primed subcutaneously  (SC) with 0.1 ml tuber extract
mixed with 50 µg ml-1 of butyl16-p(AA) on day 0 and received oral boost immunisations
on day 21, 23, and 25. Mice were immunised with tuber-derived E2 + LTB
(pL4+14#109), LTB-E2  (pL1317), and control tuber extract respectively. Mice were
sacrificed on day 35 or on day 42. Control animals were immunised with control
tubers (pBINPLUSPAT).
Sample collection
Serum samples were collected at several time intervals from tail blood. Four to six
fresh faeces pellets were collected and pre-treated as described previously [6]. From
some groups, intestinal scrapings were collected on the day of sacrifice as described
before [13].
Antibody determination by ELISA
High binding ELISA plates (Greiner, Nürtingen, Germany) were coated overnight at
4°C with 0.1 µg ml-1 of  LT (Sigma) dissolved in PBS or with 2.5 µg ml-1 of  recombinant
CSFV E2 produced in insect cells using a baculo expression vector, in coating buffer
(ID-Lelystad, pH 9.6). ELISA plates (Polysorb, Nunc) were coated overnight at 4°C
with 2.5 µg ml-1 CPV dissolved in coating buffer (ID-Lelystad, pH 9.6) [14]. Serum
and faeces samples were twofold serially diluted in PBS, 0.05% Tween 20, and 1%
bovine serum albumin. ELISA was performed as described earlier [6].
Extinctions were measured at 450 nm and antibody titres were expressed as the
dilution factor of the sample giving an extinction value of 1 above the background.
Geometric mean titres (GMT) of individual 2-log titres, standard deviation (SD),
standard error of the mean (SEM) and antilog (2GMT) values were calculated. Statistical
analysis was performed by Students two-tailed t-test. Differences between groups with
P value < 0.05 were considered to be significant.
Results
Tuber-derived vaccines
The tubers used in this study were selected on basis of accumulation of significant
amounts of  the vaccine in fresh tubers. pL4, pL1317 and pL4+14#109 tubers were
chosen on basis of  Gm1 receptor binding of  LTB subunit. The amount of  CSFV E2
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Table 5.1 Anti-LT IgG1 responses in serum in subcutaneously primed mice.
prime immunisation boost immunisation anti-LT IgG1
    antigen route of
immunisation
LTB per
dose (µg)
route of
immunisation
LTB per
dose (µg)
day 14 day 35
control tuber SC - -- -- < 1 < 1
E2 + LTB SC 2.9 -- -- 2.8 ± 1.0 5.7 ± 1.5
E2 + LTB SC 2.9 Tuber 50 3.0 ± 0.3 4.6 ± 1.1
E2 + LTB SC 2.9 IG 11.7 4.3 ± 1.7 6.6 ± 1.1
E2-LTB SC 0.05 -- -- <1 <1
E2-LTB SC 0.05 tuber 0.75 <1 <1
E2-LTB SC 0.05 IG 0.2 <1 <1
Antibody titres are given as GMT ± SEM. Mice were primed subcutaneously on day 0 with 0.1 ml tuber extract together with adjuvant.
Oral boosts were given on day 21, 23, and 25 as 5 g of intact tuber or as 0.4 ml tuber extract. Antibody titres of boosted and non-boosted
mice were not significantly different. For E2 + LTB, plant (4+14)-109 harbouring 280 nM LTB was used. This plant also contained 8
ìg of E2 per gram fresh weight tuber. For E2-LTB, plant 1317 harbouring 3.95 nM LTB was used. As a control, transgenic plants
harbouring an empty tuber expression cassette was used.
glycoprotein was estimated by Western blotting using known amounts of  CSFV E2
produced in a baculo system. Expression levels of  LTB-E2 in tubers of  pL1317 were
very low compared to LTB only (pL421), most likely because of  the enormous size of
the fusion protein (mol. wt. of  LTB-E2 is 50 kDa compared to 11 kDa for LTB)
Subcutaneous immunisation with tuber extracts
Expression levels of the concentrated antigens isolated from tuber by extraction,
dialysis and freeze-drying were determined by Gm1 ELISA and Western blotting. To
determine the immunogenicity of  the various LTB vaccines, antibody responses were
measured after subcutaneous (SC) immunisation of 0.1 ml tuber extract with butyl16-
p(AA) as adjuvant. E2 + LTB was immunogenic upon SC immunisation revealing anti-
LT IgG1 but not IgA in serum (Table 1). No responses against the co-expressed CSFV
E2 or to the fused E2 present in pL4+14#109 and pL1317 respectively, were detected.
The antigen dose for SC immunisation was very low for all tuber constructs (Table 1).
Experiments were performed with one dose for each vaccine and hence a correlation
between dose and immune response could not be determined. Antibody responses in
faeces could not be detected (data not shown).
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Table 5.2 Anti-LT IgG1 responses in serum in naive mice.
prime immunisation boost immunisation anti-LT IgG1
    antigen route of
immunisation
LTB per
dose (µg)
route of
immunisation
LTB per
dose (µg)
day 14 day 35
E2 + LTB tuber 50 tuber 50 2.7 ± 1.3 2.3 ± 1.0
E2 + LTB IG 11.7 IG 11.7 < 1 < 1
E2-LTB tuber 0.75 tuber 0.75 < 1 < 1
E2-LTB IG 0.2 IG 0.2 < 1 < 1
Antibody titres are given as GMT ± SEM. Mice were primed orally on day 0, 2, and 4, and boosted on day 21,
23, and 25.
Oral immunisation of naive mice
Mice were immunised orally either by feeding intact tuber or by intragastric (IG)
administration of tuber extract according to a triple dose schedule [12]. Most animals
ate more than 2.5 gram tuber within 24 h. Oral intake of  E2 + LTB tubers but not IG
administration of  tuber extract revealed low but significant anti-LT IgG1 titres in serum
on day 14 (Table 2) in contrast to previous experiments where intragastric immunisation
experiments performed best [6,15]. IgA was not induced. Oral boosting (either with
tuber or tuber extract) did not enhance these responses. No immune responses against
the co-expressed or fused E2 and CPV were observed. In addition, antibody responses
against LTB, E2 or CPV in faeces were not detected (data not shown).
Oral immunisation of primed mice
To enhance the immune response against orally administered antigens, we applied the
systemic priming/oral boost strategy [16]. Subcutaneously primed mice were orally
boosted either by feeding with of  tuber or IG administration of  tuber extract. To
determine the effects of  the oral booster, one group was primed but not boosted.
Oral boosting with E2 + LTB did not significantly increase the anti-LT IgG1 titre
compared to non-boosted animals. Neither did it boost the antibody response against
E2.  Oral boosting with E2 + LTB only slightly increased the IgA response (data notshown). Neither IgG1 nor IgA were detected in faeces (data not shown). In addition,
intestinal scrapings of  mice immunised with E2 + LTB were collected on day 35 and
tested on presence of  antigen-specific antibodies. Compared to groups immunised
with control tubers, we found significantly higher anti LT IgA titres in groups fed with
E2 + LTB tubers but not in the groups administered IG with tuber extract (Fig. 1).
Intestinal IgG1 was not enhanced by oral immunisation and anti-E2 antibodies were
not detected.
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Table 5.3 Number of animals that were ill/died/tested after the oral boost.
Priming booster E2 + LTB E2-LTB Total
tuber tuber 0/0/5 2/1/5 4/2/20
IG IG 0/0/5 0/0/5 1/1/20
SC - 0/0/5 0/0/5 0/0/20
SC tuber 1/1/5 1/0/5 7/2/20
SC IG 0/0/5 0/0/5 3/0/20
Total 1/1/25 3/1/25 15/5/100
During the experiments, all mice were clinically observed. Ill mice suffered from nausea and, when fed tuber,
refused to eat. In that case they were fed oat to recover or they died within 3 days.
Clinical observation of  mice after oral boost immunisation
During the experiments, we monitored daily the conditions of  the animals. We observed
side effects after oral intake of  raw potatoes. The mice displayed signs of  nausea and
reduced appetite and refused to eat the whole 5 gram of  potato. Table 3 summarises
the number of  affected and dead mice as well as the total number of  mice. To recover,
the mice were fed oat instead of the vaccine. Complications only occurred after the
booster and within three days after immunisation. No correlation could be found
between route of  priming or boosting.
Discussion
In the present study, we explored the efficacy of  edible vaccines based on the B
subunit of  the heat-labile enterotoxin of  E. coli (LTB). The CSFV E2 glycoprotein was
expressed as fusion protein with LTB and produced in potato tubers and compared
with CSFV E2 and LTB co-expressed in tubers order to establish the role of  conjugation.
It has been proven by many others that LTB and CTB (B-subunit of  the Vibrio cholerae
toxin) are not only effective mucosal immunogens but act also as adjuvant towards
antigens co-administered [17-19]. The strongest response was obtained when antigens
were conjugated chemically to LTB or CTB [20]. Others and we demonstrated that
LTB and CTB can be produced in their pentameric forms and with their ability to bind
to GM1 gangliosides in plants, e.g. in tobacco [4], maize [5] and potato [4,6-10]. Oral
administration of these plants in mice [4,6,7,10] or in humans [6,21] induced systemic
and local antibody responses and conferred protection against a subsequent challenge
with the natural toxin [7].
The immunogenicity of  the plant produced proteins, was determined by a single
subcutaneous (SC) injection of  tuber extracts plus adjuvant in mice. E2 + LTB and
CPV-LTB appeared to be immunogenic and elicited IgG antibodies against LT in serum.
Responses were low or absent which was explained by the low antigen dose varying
between less than 1 µg and a few µg. In our previous study with LTB alone, the dose
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Figure 5.1
Anti-LT IgA antibody titres in intestinal scrapings on day 35, two weeks after oral
boost immunisations with E2 + LTB tuber material. Control mice were immunised
with tuber material transformed with an empty vector. An asterisk indicates
significant responses induced by the oral boost.
was about 50 µg. [6]. Immunisation with extracts with E2-LTB did not result in detectable
responses most probably due to extremely low doses. These constructs were not further
examined.
Mice with a body weight of between 20 and 40 g have a maximal daily intake of
about 5 g potatoes. Feeding this quantity of  pL4+14#109 (E2 + LTB) tubers to naive
mice corresponded with a dose of  50 µg LTB. It induced significant anti-LT IgG1
(Table 2, day 14) but not IgA in serum. Intragastric (IG) administration of  E2 + LTB
tuber extract corresponding with about 11.7 µg LTB did not induce an immune response.
This was in contrast with our previous findings that feeding with 65 µg LTB was less
effective than IG administration of  2 µg LTB. We then suggested that besides the
antigen dose, the route of administration could be crucial for the outcome of oral
immunisation [6] because the gastro-intestinal tract is originally not designed to respond
immunologically towards orally administered food antigens [22]. Instead, oral tolerance
is induced [1]. In contrast, we now observed that E2 + LTB tubers are capable to
trigger the immune system whereas tuber extract is not.
Oral boosting of SC primed mice did not enhance the IgG1 or IgA response in
serum (Table 1) or in faeces (data not shown). This did not corresponded to our
previous study where we demonstrated that oral immunisation with plant produced
material augmented the IgA titre [6]. However, in the present study significant IgA
responses were observed in intestinal scrapings after boosting with E2 + LTB tubers.
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LTB did not enhance the immune response against co-administered or fused proteins
although correct assembly of the fusion proteins in potato plants and intact GM1-
binding in ELISA. Most probably, the E2 and CPV doses were too low to induce an
immune response, despite the use of  LTB. LTB is a weaker adjuvant than both the
toxic holotoxin and LTA [17] but toxicity of  the latter two hampers their clinical use.
Recently, non-toxic forms retaining mucosal adjuvanticity have been created by site-
directed mutagenesis [23-28]. These mutant toxins are interesting adjuvant candidates
for future transgenic edible vaccines.
All oral immunisations were preceded by overnight fasting to enable quick consumption
of the tuber material by mice. Animals were monitored daily during the experiments
and no abnormalities were seen after parenteral and oral priming. After the oral boosters,
some of  the animals were clearly affected for one or a few days. Weight loss of  more
than 5 g was noted and even mortality was observed. These systemic side effects were
noted from day the first day of booster on and disappeared within the subsequent 24
h. These adverse reactions were registered only after the boost and not after priming.
But we do not have proof that these reactions were the result of priming using a total
protein extract of tuber, giving rise to immune responses to many tuber proteins resulting
in loss of oral tolerance and/or induction of an allergic reaction. It can also be the
consequence of changes in the material administered. Being a member of the family of
solanaceae, potatoes contain several toxic glycoalkaloids, socalled solanins, with the
highest levels found in the foliage, blossoms and sprouts, followed by the peel and the
tuber flesh [29,30]. These solanins can cause haemolytic and hemorragic damage to the
gastrointestinal-tract if ingested in excess of a few mg per kg body weight [31]. They
are not destroyed by boiling and cooking of potatoes and its concentration can increase
substantially on exposure to light, environmental changes during growing seasons and
harvest, and as a result of  mechanical injury, including peeling and slicing [29,32,33].
However, the dosage of these compounds is least in peeled tubers which was the
material used for immunisation and is expected to be absent in the extracts that were
dialysed for several days. Another, less aggravating immunisation protocol must be
developed to overcome these adverse effects of edible vaccines or another, non-toxic
plant species (e.g. banana or corn) should be used.
In summary, we demonstrated that E2 co-expressed with LTB but not E2 fused to
LTB was immunogenic and E2 + LTB evoked serum responses towards LT after SC
priming and oral feeding of  mice. Feeding boosted the local but not the serum response.
LTB, however, could not act as an adjuvant towards E2. CPV-LTB was immunogenic
upon SC but not upon oral immunisation.
Oral immunisation using edible vaccines remains an attractive concept, but several
problems must be solved before an effective edible vaccine is available. First, expression
levels of recombinant proteins in plants must be increased. Second, appropriate plants
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or plant parts should be selected. And third, appropriate mucosal adjuvants should be
incorporated.
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Summary
To evaluate whether vaccine administration via intragastric gavage is indicative for the
outcome of  edible vaccines, mice were orally immunised with ovalbumin (OVA) mixed
with or without Vibrio cholerae toxin (CT) in various compositions via various routes: 1)
OVA dissolved in saline and administered intragastrically (ig); 2) OVA mixed with
food extract and administered ig (food ig); 3) food chow absorbed with OVA dissolved
in saline and fed to the animals (food); and 4) OVA dissolved in saline and administered
via drinking bottles (drinking). When given to naive mice, ig and food ig but not
food or drinking induced anti-OVA IgG1 responses in serum, but oral boost
immunisations were necessary. Serum IgA was not induced. Oral boosting of
subcutaneously primed mice enhanced the IgG1 and IgA response in serum regardless
of the route of immunisation or the vaccine composition. CT did not dramatically
enhance the immune response. All immunisation routes except drinking induced antigen-
specific IgA antibody secreting cells in the lamina propria of naive mice. But antigen-
specific antibody responses in faeces were not observed.
We concluded that oral (ig) administration is distinct from oral intake. The composition
of  the vaccine (food or saline) did not influence oral administration. We thus suggested
that the route of administration greatly influenced the outcome of oral immunisation.
Although oral administration is a well-accepted route to test the potentials of oral
vaccines, our study demonstrated that it is merely indicative for the effectiveness of
edible vaccines. Studies on the feasibility of  edible vaccines should thus be performed
by eating the vaccine.
Introduction
Oral vaccination is regarded to be a safe and simple alternative for parenteral
administered vaccines. When produced in edible plants or parts thereof, the production
costs of  such a vaccine can be reduced considerably, increasing the availability and use
for both human and animals [1]. Furthermore, production of  vaccines in plants eliminates
the risk of contamination with animal pathogens such as viruses and prion proteins [2].
The first reports on oral vaccination were published when molecular biological techniques
were scarcely available. These studies were performed via intragastric (IG) gavage or
intraduonenal (ID) immunisation [3,4]. At that time, many researchers already speculated
on the development of edible vaccines and the results of IG or ID immunisation were
thought to be predictable for the efficacy of  edible vaccines. At present, only few oral
vaccines are licensed and available and all are based on live microorganisms [5].
The increasing knowledge on the virulence factors of pathogens allows the
development of non-living vaccines that are regarded to be safer than live vaccines [2].
In general, non-living vaccines are poor immunogens and adjuvants are required. The
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situation becomes even worse when such vaccines are delivered orally since passage
through the gastrointestinal (GI) tract involves many degradation steps. Only a fraction
of the initially administered material will finally arrive in the gut. It must then still pass
the epithelium in order to elicit an immune response. Degradation can be partially
overcome by encapsulation of  the antigens. In transgenic plants, plant cells can protect
the antigen against the acidic environment of the stomach [5,6] and proteolysis in the
GI tract.
Recently, we have reported studies on oral immunisation of  mice with potato tubers
expressing the B-subunit of  Escherichia coli heat labile toxin (LTB).  We observed that
feeding intact tuber was less effective than IG gavage of tuber extract containing a
similar antigen dose. We then suggested that the route between mouth and stomach or
the vaccine formulation is a crucial factor for the outcome of  oral immunisation [7]. In
the present study, we evaluate both possibilities. Mice were orally immunised with plain
ovalbumin (OVA) or OVA incorporated in standard mice chow in order to mimic
edible vaccines.
Materials and methods
Mice
Swiss female mice (6 to 8 weeks old) were obtained from Charles River (Sulzfield,
Germany). Animals immunised via intragastric (ig) gavage were housed per group under
conventional conditions. Animals immunised by food or drinking water were housed
individually. All mice were raised and kept on an OVA free diet. All animal experiments
were held under auspices of  the ID-Lelystad B.V. Animal Experimentation Committee
according to the Dutch Law on Animal Experimentation.
Antigen preparation and immunisation
Four antigen preparations were tested:
1) Ovalbumin (OVA; Grade V, A-5503, Sigma) was dissolved in saline at a final
concentration of 10 mg per 0.4 ml with or without 5 µg cholera toxin (CT; C-
8052, Sigma) and administered via ig gavage (ig).
2) A food extract of  standard food chow dissolved in saline was made. Subsequently,
OVA was dissolved in this food extract at a final concentration of  10 mg per 0.4
ml with or without 5 µg CT and administered via ig gavage (food ig).
3) OVA was dissolved in saline at a final concentration of  10 mg per 0.1 ml with or
without 5 µg CT and added to standard food chow of about 1 g until completely
absorbed. A single treated chow was given to individual mice (food).
4) OVA was dissolved in saline at a final concentration of  50 mg OVA per 50 ml with
or without 25 µg CT. Standard drinking bottles were filled with 50 ml of  this
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antigen preparation and given to individual mice (drinking). The drinking bottles
were weighed before and after immunisation.
Mice were fasted overnight before each oral immunisation (water was provided ad
libitum). The groups immunised via the ig route, received standard food 2 h after gavage.
The food and drinking preparations were given for 24 h after which the animals
received standard food.
Groups of naive mice were primed orally on day 0, 2, and 4, and boosted orally on
day 21, 23, and 25. Other groups were primed subcutaneously (sc) on day 0 with 100
µg OVA and 50 µg Butyl16-p(AA) in 0.1 ml phosphate buffered saline and subsequently
boosted orally on day 21, 23, and 25.
Collection of faeces and serum samples
Serum and faeces samples were collected before immunisation and on day 14 and 35.
Four to six fresh faeces pellets per mouse were collected and pre-treated as described
previously [7].
Detection of antibody secreting cells by ELISPOT
From some groups, lamina propria lymphocytes were isolated from the small intestine
and OVA-specific antibody producing cells (APC) were determined by ELISPOT as
described before [8].
Detection of  anti-OVA antibodies by ELISA
High binding ELISA plates (Greiner, Nürtingen, Germany) were coated overnight at
4°C with 100 µg ml-1 OVA dissolved in PBS (pH = 7.4). ELISA was further performed
as described earlier [7]. Antibody titres were expressed as the dilution factor of the
sample giving an extinction value of 1.0 above the background. Geometric mean titres
(GMT) of individual 2-log titres and standard error of the mean (SEM) values were
calculated. Statistical analysis was performed by Students two-tailed t-test. Differences
between groups with P value < 0.05 were considered to be significant. Extinctions
below detection limit were considered to have a GMT of -10.
Results
Oral immunisation of naive mice
All food immunised mice ate the treated chow within 24 hours. The drinking groups
drank 10 ml on average, which corresponded with an oral intake of  10 mg OVA. Oral
priming of  naive mice did not evoke OVA-specific IgG1 or IgA antibodies in serum.
Oral boosting induced OVA-specific IgG1 antibodies on day 35 after ig or food ig
administration but not after oral intake of  food or drinking water (Fig. 6.1A). The
differences between ig and food ig were not significant. Serum IgA antibodies were
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Figure 6.1
The immune response after oral immunisation of naive mice. Naive mice were
primed on day 0 and boosted on day 21. CT was used as adjuvant. Samples were
collected prior to immunisation. Anti-OVA specific IgG1 (A) and anti-OVA specific
IgA (B) in serum. The mean 2-log titre ± SEM for five mice in each group is shown.
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not detected after the boost (Fig. 6.1B). No antibody responses were detectable in
faeces (data not shown).
Oral immunisation of primed mice
Subcutaneous (sc) priming of  mice with OVA plus Butyl16-p(AA) as adjuvant elicited
anti-OVA IgG1 but not IgA in serum (Fig. 6.2A and 6.2B). Subsequent oral boosting
significantly increased the IgG1 titre compared to non-boosted animals regardless of
the route of immunisation or the vaccine composition. The IgA titre was increased in
all groups except in the sc/food ig(-) and sc/food(+) groups, but the titre was only
significant in ig boosted mice. Addition of CT only significantly increased the immune
response after drinking immunisation.
ELISPOT analysis of lymphocytes of the lamina propria of the small intestine
The presence of  OVA-specific antibody secreting cells (ASCs) in the lamina propria
of  the small intestine were measured only in orally primed and boosted animals. Anti-
OVA IgA but not IgG1 ASCs were observed (Fig. 6.3). The highest number of  anti-
OVA ASCs were observed after food ig immunisation, but ig and food immunisation
also induced significant antigen-specific IgA ASCs.
Discussion
Previously, we demonstrated that antigen-specific immune responses after feeding of
LTB-expressing potato tubers were weaker than after intragastric (ig) gavage of  tuber
extract, although the amount of  LTB in intact tubers was 30 times higher [7].  We
suggested that the method of  administration caused these differences. Protein degradation
in the gastrointestinal (GI) tract is an important factor in the outcome of oral vaccination.
At the beginning of the GI tract, mastication breaks food into smaller pieces, thereby
aided by proteolytic enzymes in the saliva. Subsequently, the food suspension is transported
to the stomach with its low pH and finally arrives at the small intestines, where the M-
cells reside. In the experiments described here, mice were immunised orally with different
formulations of  ovalbumin (OVA) via different routes. By addition of  a fasting period,
we assumed that the length of  stay in the stomach was similar in all animals. And antigen
administered via food or drinking water but not via ig gavage was subjected to the
passage from mouth via oesophagus into the stomach.
In a first experiment ig gavage with OVA dissolved in saline (ig) was compared to
immunisation of mice with chow added with the antigen (food). In accordance with
our observations with transgenic potatoes [7], we observed that ig immunisation was
more effective than food and, in contrast to the transgenic potato study, the antigen
doses were similar (data not shown). However, besides the difference in route, the
vaccine composition was an additional difference.
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Figure 6.2
The immune response after oral immunisation of primed mice. Mice were primed
subcutaneously on day 0 and orally boosted on day 21. Control groups were not
boosted (sc/-). CT was used as adjuvant in groups indicated with an +. Samples were
collected prior to immunisation. Anti-OVA specific IgG1 (A) and anti-OVA specific
IgA (B) in serum. The mean 2-log titre ± SEM for five mice in each group is shown.
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To determine the role of  food components in oral immunisation, we repeated the
experiment with two additional groups: one group received the antigen via drinking
water (drinking) and another via ig gavage of the antigen dissolved in an extract of
mice feed (food ig). Again, ig gavage was more effective than food immunisation
regardless of the vaccine composition (saline or chow extract). ig gavage was also
more effective than drinking immunisation. This corresponded with findings of  Felder
et al who directly injected microparticles into the mouth of pigs instead of IG gavage
and observed no immune responses [9].
Surprisingly, in subcutaneously (SC) primed mice, drinking was more effective than
food immunisation. This suggested that chow components still might have played a
role in the outcome of oral vaccination. The primary task of the GI tract is absorption
of  nutrition out of  food and under normal conditions, the body is tolerant against
dietary antigens and immunological reactions are preferably prevented [10]. Perturbation
of  the balance in the gut may lead to unwanted diseases like food allergy, Crohns
disease, and coeliac disease as a result of  breakdown in oral tolerance [11]. Taking the
natural function of  the GI tract into account, it is not remarkable that OVA mixed with
food is less effective in evoking an immune response than OVA dissolved in an aqueous
phase. The body probably recognises OVA mixed with food as normal food, and
does not react on it. On the other hand, food IG immunisation evoked serum IgG1
and high numbers of  IgA ASC. This suggested that orally administered antigens were
only recognised as food when it follows all processing steps, including passage through
the mouth and oesophagus. The route of  administration is probably a crucial factor in
the outcome of  oral vaccination. Food induced significant numbers of  APC, so it is
not likely that oral tolerance was induced. Future studies must assess whether food
immunisation is not immunogenic or induce oral tolerance instead. Our results
corresponded with observations of  Klipper et al. who reported that administration of
bovine serum albumin (BSA) in solution induced immune responses whereas feeding
of BSA powder mixed with standard food induced tolerance [12,13]. In contrast to us,
Klipper et al. concluded that the physical form of  an antigen was an important factor
for oral immunisation.
We fasted the animals to reduce duration of  stay in the stomach. After fasting, food is
released by the stomach as a bolus. This might have influenced the food IG and food
immunisations, but not the other two. The efficiency of  vaccine take up out of  a bolus
may be more difficult. This may be another explanation of the reduced effectiveness
of food immunisation, and must be also taken into account when designing an edible
vaccine.
Similar to previous experiments of our group [7], oral immunisation of naive mice
was less effective than oral boosting of subcutaneously (SC) primed mice. Although all
naive mice were immunised with cholera toxin (CT) as adjuvant. Subcutaneous priming
with Butyl16-p(AA) as adjuvant triggered the immune system for an oral booster. When
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Figure 6.3
Detection of OVA-specific antibody secreting cells (ASC) in the lamina propria
lymphocytes of orally immunised naive mice. Control mice were not immunised. The
mean number of ASC per 106 lamina propria lymphocytes (LPL)  ± SEM are shown.
the immune system was sufficiently triggered, all administration routes boosted the
immune response, regardless of  the vaccine composition and the use of  CT.
Surprisingly, IgA was not the predominant immunoglobulin induced by oral
immunisation and IgG1 was also induced. In serum, very low IgA titres were measurable,
but that was consistent with the observations that IgA is predominantly present in
mucosal secretions. This was confirmed by ELISPOT, which revealed that IgA and not
IgG1 antibody secreting cells (ASCs) were present in the lamina propria of the small
intestine.
Oral immunisation by oral intake of food an attractive concept because of its ease of
administration. Various studies have been reported the use of  virus-like-particles (VLPs)
or non-living vaccines expressed in plants [7,14,15]. Preliminary human trails have been
published [16,17]. However, the development of transgenic plants is laborious and
time-consuming. Anticipating to future edible vaccines, studies are performed by oral
administration of antigen by IG gavage. The present study demonstrated that oral
administration is distinct from oral intake of food and may overestimate the efficacy
thereof.
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Mucosal immune responses upon oral vaccination
The efficacy of  vaccination via the oral route was evaluated first. This was determined
by measuring the antigen-specific titres in faeces, intestinal scraping and blood samples.
Oral vaccines are known to induce both mucosal and system immune responses [1].
Mucosal immune responses are dominated by immunoglobulins of  the IgA isotype and
are best monitored in mucosal secretions. Surprisingly, we found the highest antigen-
specific antibody titres in blood and these were of  the IgG1 isotype. IgA antibodies
were hardly measurable, especially not in faeces or intestinal scraping (Chapters 2, 3, 4,
5 and 6). It was not expected that the systemic immune response was predominant, but
we experienced difficulties in determining the mucosal immune response. In our hands,
low mucosal responses were measurable in faeces after oral immunisation with OVA
with or without CT (Chapters 2, 3) or transgenic potatoes expressing LTB (Chapter 4)
and in intestinal scrapings after oral immunisation with transgenic potatoes expressing
LTB-fusion proteins (Chapter 5).
Besides immunological active components, mucosal secretions contain other functional
substances. Secretions in the gastrointestinal (GI) tract play a major role in the digestion
of  food and for this purpose, proteolytic enzymes are abundantly present. Although
immunoglobulins, especially sIgA, are relatively insensitive to proteolytic degradation,
the enzymes may still interfere with the test system. Therefore protease inhibitors were
added to the secretion samples, which slightly diluted the antibodies present in these
samples. Another reason why blood titres are higher may be that blood is a closed
compartment where antibodies are circulating. Mucosal antibodies, on the other hand,
are constantly secreted.
Although mucosal secretion samples were collected on the same days as blood samples,
Van der Heijden et al. has observed significant day to day fluctuations of  the mucosal
response [2], thus repeated sampling would be more appropriate for a better evaluation
of  the mucosal immune response. Animal samples were collected every week in the
here described experiments, but for future studies daily collection is recommended to
obtain more insight in the mucosal immune response. Measurement of  antibodies in
intestinal scrapings has restrictions because a single animal can be sampled only once.
High titres in blood were always found together with low but detectable responses in
secretions and low titres were accompanied by absence of  a mucosal response. Faeces
IgA titres were lower than serum IgA titres (various Chapters). This is in agreement
with findings of  Jertborn et al. [3], who found that serum IgG and IgA are indicative for
the sIgA response. Others, however stated that blood reflects only systemic and not
mucosal immunity [2,4].
Analysis of  the antibody-secreting cells (ASCs) in the mucosal associated lymphoid
tissue (MALT) is another, probably more sensitive method to quantify the number of
activated and mature plasma B-cells [5]. Most antigen-specific ASCs in the MALT isolated
95
General discussion
after oral immunisation produced antibodies of  the IgA isotype. An easier and less
laborious method might be measurement of  ASCs in blood. Blood ASCs elicited by
oral vaccination are proven to home to mucosal tissues and are independent from serum
antibody responses. But since sensitivity of  measurement on blood ASCs is low, these
are not appropriate alternatives for MALT-derived ASCs to measure the mucosal immune
response [6].
Interpretation of  the antibody titre into protective levels is rather complicated. The
protective value of  the antibody responses elicited by the transgenic potatoes was not
validated. In a study on oral immunisation with virus-like-particles (VLPs) of  rabbit
hemarraghic disease virus (RHDV) in rabbits, significant protection against a subsequent
challenge with virulent virus were observed, while the IgA titre in serum was 64 at
maximum (manuscript in preparation). Such protection against an infection with virus
or bacteria despite low IgA titres have been confirmed by others [7]. So, relatively low
antibody titres can still be successfully protective.
An applicable immunisation protocol for edible vaccines
Oral immunisation has proven to be more successful when the vaccine was administered
frequently, preferably on several consecutive days, followed by boost immunisations
three to four weeks later [8-11]. This immunisation protocol had to be optimised in the
light of  potato tuber as edible vaccines. The frequency of  feeding of  raw potatoes to
mice was limited by the maximal oral intake, the lack of  nutritional value and the presence
of  toxic ingredients. Immunisation on consecutive days was therefore undesirable,
because daily repeated immunisations with potatoes appeared to be too aggravating for
the animals. A protocol was designed in which the animals were immunised on alternating
days. First, the protocol was optimised using a soluble protein: ovalbumin (OVA). IG
priming and boosting with OVA on three alternating days (triple dose) resulted in
higher responses in serum than single immunisations. Local responses were only obtained
after triple dose immunisation and CT was necessary as adjuvant. Immune responses
against this toxin were also elicited (Chapter 2). Then it was investigated whether oral
immunisations were more effective in a primed immune system. Chapter 3 describes
that subcutaneous (SC) or intraperitoneal (IP) immunisations with OVA could prime
the immune system for a subsequent oral booster. Interestingly, use of  an adjuvant in
the priming significantly increased serum IgA and, to a lesser extend, IgG1 upon the
booster. As we expected, oral boosts significantly enhanced the serum IgA titres in
systemically primed mice compared to naive mice. Although this was independent of
the use of  CT, the use CT was continued in order to maximise the mucosal immune
response. However, the maximal IgA titre in serum was on average 128 and the maximal
IgA titre in faeces or intestinal scrapings was 8 when CT was used.
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Oral boosting of  primed mice with triple doses and CT as adjuvant induced antibody
responses in faeces whereas local responses were not significant with single dose boosts.
This systemic priming/oral boost strategy was first described by Pierce et al. who found
that SC/oral immunisation of  dogs with cholera toxoid enhanced the anti-toxoid response
in serum and duration of  protection against a challenge with live bacteria [7]. Local
responses were not determined in the study of  Pierce, but antigen-specific ASCs were
found in the small intestine and other lymphoid organs by Van der Heijden et al. [5].
Chapter 3 clearly demonstrated that antibodies were secreted and detectable in faeces
when the parenterally primed animals were boosted with triple doses of  the antigen.
One explanation of  how a parenteral immunisation can prime the mucosal immune
system (MIS) for a subsequent booster is that systemic immunisation generates a
population of  primed lymphocytes. This results in increased responsiveness to relatively
small amounts of  antigen that pass the physical barrier of  the GI tract. Another
explanation is that systemic priming activates the expression of  mucosal homing receptors
on the surface of  antigen-specific lymphocytes. How and where these lymphocytes are
induced by systemic immunisation remains obscure [12]. But homing of  primed
lymphocytes to the MALT results in a population of  memory cells and a state of  increased
responsiveness of  the MALT. Upon an oral antigen booster, the primed MALT will
develop a secondary response manifested by IgG and IgA antibodies (Chapter 3)
Since it was already known that expression levels of  recombinant proteins in plants
could be very low, we determined the minimal effective oral dose of  OVA. Oral boosting
of  SC primed mice required doses of  at least 300 µg OVA provided that CT was added
as adjuvant. Without this adjuvant, this minimal effective dose was significantly higher.
Van der Heijden et al. demonstrated that without CT, systemically primed mice must be
boosted orally with at least 10 mg OVA [5]. These results again demonstrated that large
amounts of  antigen are needed.
Taken together these findings, an immunisation protocol for mice was proposed which
involved SC priming on day 0 with 100 µg antigen plus 50 µg of  the adjuvant Butyl-16-
p(AA) [13] and an oral booster with three doses of  at least 300 µg antigen plus 5 µg CT
three to four weeks later. In retrospect, evaluation of  this protocol with LTB or CTB
instead of  CT as adjuvant would have been more appropriate since the protocol was
intended to be used with edible vaccines expressing LTB with or without co-expressed
antigens.
Chapter 4 describes the application of  this immunisation protocol with edible vaccines
expressing LTB as immunogen. SC priming with tuber extract followed by triple dose
oral boost immunisations appeared to be efficient in inducing serum and faecal IgA. A
decrease in body weight of  the animals during the immunisation period was observed
(data not shown), which was considered to be caused by the intense immunisation
schedule, including three oral immunisations on alternating days which were preceded
by an overnight fasting period. This immunisation protocol affected the general condition
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of  the animals resulting in clear morbidity for one or a few days and even mortality in a
few cases in one experiment (Chapter 5).
The studies described in Chapter 2 revealed that a second series of  triple dose boost
immunisations further enhanced the serum IgA response while the other responses
were maintained at the same level. Cebra reported that cells in the germinal centres of
Peyers Patches (PPs) were transient and that successful secretory IgA responses
attenuated the stimulation by secondary mucosal challenge. This may explain why
traditional boost responses are often not induced after oral immunisation [14].
Furthermore, the duration of  the response must be assessed in order to establish the
optimal time intervals for subsequent oral boost immunisations. We have only followed
the immune response until three to four weeks after the last boost. Lycke et al. however,
demonstrated that up to two years after an initial series of  oral immunisation with CT,
a single oral boost with 10 µg CT evoked a clear anti-CT IgA response in the lamina
propria [15]. This indicated that long-term memory in the gut could be established.
Edible vaccines based on LTB
Edible vaccines were made in potato plants under control of  the tuber specific patatin
promotor. The first transgenic plant generated contained expressed recombinant LTB
(pL421). Then, other transgenic plants were constructed for production a LTB-fusion
protein. For this purpose, the potato cultivar Desiree was transformed to express E2-
LTB (pL1317). LTB was also co-expressed in one plant together with E2 (pL4+14#109).
The majority of  the transgenic plants produced tubers within 2  4 months after transfer
to the greenhouse (personal communication). The expression of  GM1-binding antigens
was determined in extracts from freshly harvested tubers. Potato tubers contained
approximately 7 mg of  water-soluble protein per gram of  fresh weight tuber. Most of
the tubers analysed contained GM1-binding LTB or LTB-fusion proteins. LTB as well
as the LTB-fusion proteins were intact (including pentamer formation), as confirmed
by ELISA (Florack et al., manuscript in preparation) and Western blot analysis (Fig. 7.1).
Chapter 4 describes the use of  plant LTB as immunogen. The expression level of
GM1-binding LTB was on average 0.25% LTB per total soluble protein (TSP), which
was comparable to findings by others (Chapter 1, Table 1.1). The IG administered dose
was of  about 2 µg of  LTB and the dose by oral feeding about 65 µg of  LTB. The plant-
produced LTB was immunogenic and oral administration elicited both systemic and
local IgA responses in parenterally primed but not in naive animals. Our results
corresponded partially with those of  others. Mason et al. demonstrated that feeding of
naive mice with LTB tubers with similar antigen doses induced local IgA and the toxic
effects of  LT could be neutralised in vivo [16]. Why oral immunisation of  naive mice was
not effective in our hands was not elucidated. Despite lower dose, IG administration
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Figure 7.1
Immunoblots of LTB produced in transgenic potato tubers. Accumulation of LTB in
the tuber was demonstrated using a LTB-specific monoclonal antibody on a
nitrocellulose tissueblot. BINPLUSPAT contains the empty vector. pL401 until
pL422 contain the LTB-coding vector (A). Presence of pentameric LTB in tuber
extracts is demonstrated by westernblot analysis under semi-native conditions (B).
induced higher antibody titres than feeding of  intact tuber. This demonstrated that
other factors than antigen dose influence the outcome of  oral vaccination.
The E2-LTB-fusion protein could be produced correctly in potatoes. The expression
of  E2-LTB was more than 10 times lower (Chapter 5) than LTB alone as reported by us
(Chapter 4) and Mason et al. [17], most likely because of  the enormous size of  the
fusion protein. With E2-LTB, a weak response against LTB but no response against E2
was detected. Possible explanations are too low dose of  E2 or relatively too rapid
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degradation of  the antigen. Apparently, LTB did not function as an adjuvant for E2
(Chapter 5). Co-expression of  LTB with E2 (E2 + LTB) again induced antibody
responses against LT only and not against E2.
Degradation of  the edible vaccine in the GI tract could also have been responsible for
the poor efficacy of  LTB as adjuvant. Transport studies in the human intestinal epithelial
cell line Caco-2 with radioactively labelled LTB revealed that after two hours of
incubation, the radioactivity was transported from the apical to basolateral and visa
versa. Less than 1% of  the transported radioactivity could be immunoprecipitated with
anti-LTB antiserum indicating that LTB was extensively degraded during the transport
[22]. With rapid degradation and low expression levels in potatoes, it can be expected
that only a small quantity of  the vaccine finally reach the MIS. Chapter 3 demonstrated
that 300 µg of  OVA was the minimal effective dose for oral immunisation. Increase of
expression levels in plants might improve the probability of  success. Furthermore, the
use of  another, more potent adjuvant is desirable. In general, LTB and CTB are weaker
adjuvants than the complete holotoxin [23] but toxicity of  the latter has hindered its
practical use. Non-toxic mutants of  LT and CT that have been developed recently
[20,24-26] are interesting adjuvant candidates for future edible vaccine studies.
Oral immunisation versus oral tolerance
The antibody responses we measured in serum and faeces were low or, in some cases,
totally absent. There is a major paradox in oral vaccination: feeding of  vaccines must
result in protective immune responses instead of  oral tolerance (Fig. 7.2). Normally, the
GI tract does not develop an immune response against food components but is tolerant
towards them [27]. With edible vaccines, the MIS must be told that the transgenic potato
is not a common potato but contains a vaccine, and that the MIS must respond to this
vaccine but not to the potato itself.
The biological function of  the immune system is first and foremost to protect against
dangerous pathogens. Live microorganisms are able to infect and invade the host, cause
damage and generate danger signals that stimulate and activate immune responses [28].
Non-living antigens without adjuvant lack danger signals and are therefore less effective
than live vaccines. Obviously, food products do not contain these danger signals.
Perturbation of  the physiological balance in the GI tract might lead to the unwanted
situation in which food induces mucosal immune responses and diseases like food allergy
or coeliac disease can be induced. An edible vaccine must therefore provide the necessary
signals for an immune response, because food normally does not. The response must,
however, be controlled to prevent unwanted diseases.
Remarkably, the systemic prime/oral boost protocol was successful for oral boosts
immunisations, whereas oral boosting of  naive mice was often unsuccessful. We
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Figure 7.2 
The oral vaccination paradox: oral vaccination is intended to active, protective 
immunity against pathogens invading mucosal tissues, but the GI-tract is 
programmed to respond with a state of immunotolerance against oral antigens 
suggested that this immunisation protocol could prevent oral tolerance, because an
established immune response is difficult to tolerise (Chapter 3).
Although systemically primed mice could be tolerised by feeding OVA, the degree of
tolerance and its effects on the systemic immune response were more limited than that
found in equivalent naïve animals [29]. This indicates that induction of  oral tolerance is
relatively ineffective in a situation with an established immune response [30]. Antigen-
experienced T cells may be inherently resistant to tolerogenic signals, perhaps because
their increased expression of  adhesion molecules and altered signalling pathways make
them less dependent on co-stimulation for their activation than naïve T cells [29].
Adoptive transfer studies with lymphocytes of  orally treated animals are needed to
proof  oral tolerance. Recipients should not respond to a systemic immunisation. These
type of  experiments were not performed. Therefore, the role of  oral tolerance in our
experiments could not be determined. Nevertheless, study of  this phenomenon is an
important consideration in further studies on edible vaccines. Especially since induction
of  oral tolerance using edible vaccines might broaden the application area of  such
TOLERANCE IMMUNE
RESPONSE
ORAL IMMUNISATION
?
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vaccines. Oral tolerance induction can be exploited as immunotherapy for diseases like
allergy or some autoimmune diseases [31]. Williams et al. summarised the use of  LTB
and CTB conjugates for the induction of  tolerance as immunotherapy for experimental
allergic encephalomyelitis (EAE) in the rat and diabetes in the nonobese diabetic (NOD)
mouse.
Edible vaccines as genetically modified organisms; the public opinion
The development of  transgenic plants with improved production or resistance has
initiated public debate and awareness on the subject. Although edible vaccines have
obvious advantages, the use of  transgenic plants distress critics. The main concern is
the introduction of  new genetically modified variants in the environment via pollen,
seeds or pieces of  root or tubers since these are capable to grow out into full transgenic
plants. In 1999, Losey et al. published a Scientific Correspondence in Nature that pollen
from corn engineered to express proteins from Baccilus thuringiensis (Bt) pose a potential
risk to monarch butterfly populations growing on milkweed. However, this controversial
publication lacked solid scientific data (e.g. missing proper controls and details such as
the dose used, the unspecified endotoxin concentration in the pollen themselves, and
the lack on information on the potential for temporal and spatial overlap of  pollen
shed, milkweed plants and monarchs under natural field conditions). The scientific
community rejected the works validity. Sears et al. reported recently that Bt expression
in pollen is low and no acute toxic effects were observed at any pollen density that
would be encountered in the field. In addition, only a portion of  the monarch populations
utilises milkweed in and near cornfields. These researchers concluded that the impact
of  Bt corn pollen from current commercial hybrids on the monarch butterfly populations
is negligible [32]. Nevertheless, the Losey et al. report was immediately embraced by the
media and the public [33]. Shelton and Sears reviewed the history of  the monarch
controversy in a special GM issue of  The Plant Journal [33]. Adequate data is not yet
available to provide an appropriate risk assessment by the scientific community. At this
moment, risk communication has been left largely in the hands of  non-scientists [34]. It
is clear that the impact of  transgenic food on its environment must be assessed with
absolute care to ensure proper, well-thought research. The results must then be evaluated
in a more reserved manner without letting emotions prevail.
Perspectives of  edible vaccines
In the early 1990s, Charles Arntzen mused about genetically engineered plants
producing vaccines in their edible parts. Ten years later, many publications and patents
have been published on this subject. The research described in this thesis, clearly
demonstrated that potato tubers could be used to produce complex (fusion) proteins
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Figure 7.3 
Characteristics of the ideal plant for edible vaccine production 
of  which LTB, E2 + LTB, and CVP-LTB producing tubers were immunogenic upon
subcutaneous immunisation. The ideal edible vaccine has high protein content and high
expression levels of  the antigen, grows rapidly under a wide range of  conditions and is
easy to propagate. Finally, the edible vaccine is not toxic when given in large amounts,
because oral vaccination may require high and repeated doses. In this respect, the use
of  potatoes has several drawbacks. Consumption of  raw potatoes is not preferable and
cooking might denature the antigen. Being a member of  the family of  solanaceae,
potatoes contain several toxic glycoalkaloids (solanins) with the highest levels found in
the foliage, blossoms and sprouts, followed by the peel and the tuber flesh [37,38].
These solanins can cause hemolytic and hemorragic damage to the gastrointestinal (GI)-
tract if  ingested in excess of  a few mg per kg body weight [39]. Solanins are not destroyed
by boiling and cooking of  potatoes and its concentration can increase substantially on
exposure to light, environmental changes during growing seasons and harvest, and as a
result of  mechanical injury, including peeling and slicing [37,40,41]. Potatoes were initially
not intended to be used as vaccine vehicles, but merely as model system to prove the
concept. However, potatoes may be practical as certain kinds of  potatoes are actually
eaten raw in South America and cooking of  potatoes does not destroy the antigen per
se [42]. Table 1.1 to 1.3 (Chapter 1) summarise the plants which have been transformed
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yet. For future edible vaccine studies, a more suitable plant like tomato with relatively
high expression levels should be chosen (Fig. 7.3).
Despite limited progress, researchers still believe in the use of  plants for medical
purposes. Besides protection against infectious pathogens, oral administration of  antigen
may be of  interest in suppressing autoimmunity. Furthermore, plants can be used to
produce therapeutical antibodies for example a chimeric IgG-IgA antibody against a
surface antigen of  Streptococcus mutans to prevent tooth decay, or to produce
pharmaceutical proteins like human serum albumin, epidermal growth factor or
interferon- [Streatfield, 2001]. The prediction that an applicable edible vaccine will be
ready in the near future is overly optimistic, however, the still increasing knowledge in
molecular biology and immunology makes it less fiction.
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ABBREVIATIONS
APC antigen presenting cells
ASC antibody secreting cells
CMIS common mucosal immune system
CPV canine parvo virus
CT Vibrio cholerae toxin
CTA Vibrio cholerae toxin subunit A
CTB Vibrio cholerae toxin subunit B
DC dentritic cells
FAE follicle associated tissue
GALT gut-associated lymphoid tissue
GI gastro-intestinal
IEC intestinal epithelial cells
ID intraduonenal(ly)
IG intragastric(ally)
IN intranasal(ly)
IP intraperitoneal(ly)
ISCOMS immune stimulating complexes
LT Escherichia coli enterotoxin
LTA Escherichia coli enterotoxin subuntit A
LTB Escherichia coli enterotoxin subuntit B
MALT mucosa-associated lymphoid tissue
MHC major histocompatibility comples
MIS mucosal immune system
MLN mesenteric lymphnode
OVA ovalbumin
PLG poly (lactide-co-glycolide)
PO per oral(ly)
PP Peyers patches
RHDV rabbit haemorragic disease virus
SC subcutaneous(ly)
TSP total soluble protein
VLP virus-like particle
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Summary
This thesis describes the research to explore the feasibility of plants for oral vaccination.
The research focussed on a model of  LTB produced in potato tubers or ovalbumin
(OVA) as antigen and tested in mice. A general introduction into the backgrounds of
oral immunisation is given in Chapter 1. The next two chapters describe the optimisation
of  an immunisation protocol for edible vaccines by addressing the following questions:
can the immune response be increased by more frequent doses of edible vaccines
without negative effects on general health (Chapter 2)?; and can the immune status of
the host be modified to react more efficiently to a subsequent oral boost (Chapter 3)?.
Ovalbumin (OVA) was used as model antigen and administered via intragastric (IG)
gavage to mice. The results of these studies led to a refined immunisation protocol in
which one single subcutaneous, adjuvanted priming is followed three weeks later by
oral boost immunisations on three alternating days (also referred to as the systemic
prime/oral boost protocol).
As a model for edible vaccines, the heat-labile enterotoxin subunit-B (LTB) of  Escherichia
coli was produced in potato tubers. This edible vaccine was either fed or administered
orally to mice. Using the optimised immunisation protocol, local and systemic responses
against LTB were induced (Chapter 4). Subsequently, the use of  LTB as adjuvant for
co-expressed antigens in edible vaccines was explored. A glycoprotein (E2) of the
classical swine fever virus was co-expressed as fusion protein to LTB or expressed
together with LTB in potatoes, resulting in E2-LTB and E2 + LTB potatoes, respectively.
LTB fused to these antigens retained its biological activity (GM1-binding). The expression
levels of  LTB varied from 0.25% in LTB-transgenic plants to 0.01% LTB per total
soluble protein in E2-LTB-transgenic plants. The levels of  LTB as fusion-proteins were
lower than those of  LTB alone or co-expressed with E2. LTB, E2 + LTB, and CVP-
LTB producing tubers were immunogenic upon subcutaneous immunisation and
significant antibody responses against LTB were detected. The response towards the
co-expressed antigens were low or undetectable. Probably, the antigen dose of  the co-
expressed antigen was too low and the adjuvant capacity of  LTB was insufficient (Chapter
5). Further research is required to improve the carrier and adjuvant function of  LTB.
Another point of  concern is that besides adjuvant activity, LT,CT and their B-subunits
are also known to be capable to induce oral tolerance. Future research must concentrate
on more effective carrier-molecules or adjuvants devoid of  tolerating properties.
The chapters 4 and 6 clearly demonstrated that IG gavage of tuber or chow extracts
induced higher antibody responses than similar doses of antigen taken up with feed or
drinking water. It was concluded that the route of  oral administration is at least as
important than the vaccine composition. The difference between feeding and oral
administration must be taken into account when the feasibility of edible vaccines is
assessed (Chapter 6).
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In Chapter 7, the general findings of this thesis are discussed. The proposed systemic
prime/triple dose oral boost protocol appeared to be applicable for oral administration
and oral intake of  edible vaccines in particular. However, significant adverse effects
were observed after tuber intake. The ideal edible vaccine in plants has sufficient levels
of antigen, is easy to propagate under a wide range of conditions and is not toxic when
given the amounts required. In this respect, the use of  potatoes has several drawbacks.
Consumption of raw potatoes is not preferable and cooking might denature the antigen.
For future edible vaccine studies, a more suitable plant with relatively high expression
levels should be chosen (e.g. tomato).
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In de strijd tegen infectieziekten zijn er in de loop der jaren verschillende succesvolle
vaccins ontwikkeld. Deze vaccins worden meestal via injecties toegediend, maar hieraan
kleven ook enkele nadelen: het gebruik van naalden houdt altijd een risico van besmetting
met pathogenen (ziekteverwekkers) in, injecties moeten door speciaal opgeleid personeel
worden toegediend en het gebruik van naalden is met name voor kinderen beangstigend.
Bij vaccins die oraal (via de mond) worden toegediend zijn geen naalden meer nodig.
De toediening van orale vaccins is verder dusdanig eenvoudig dat, in principe, iedereen
ze kan toedienen. Hierdoor zal een grootschalige vaccinatie (zoals de recente
meningococcen-vaccinatie campagne) minder tijd kosten en minder angst en stress bij
de gevaccineerde opleveren. Verder zijn orale vaccins in staat om zowel in het bloed als
in de beschermde slijmlagen van het lichaam (de mucosa) een immunologische reactie
op te wekken. Het mucosale immuunsysteem wordt hierbij geactiveerd. Bescherming
aan de mucosa is belangrijk, omdat de meeste pathogenen via de mucosa het lichaam
van een gastheer binnenkomen. Injecteerbare vaccins brengen met name immunologische
bescherming in het bloed teweeg, maar het mucosale immuunsysteem wordt nauwelijks
geactiveerd. Een voorbeeld van een succesvol oraal vaccin is het poliovaccin wat een
belangrijke bijdrage heeft gehad in de wereldwijde uitroeiing van polio. Momenteel zijn
er weinig andere orale vaccins commercieel verkrijgbaar, maar gezien de vele voordelen
van orale vaccins wordt er nog steeds intensief onderzoek naar nieuwe orale vaccins
uitgevoerd.
Met behulp van de huidige kennis in moleculaire biologie is het mogelijk om vaccins
in planten te produceren. Wanneer een oraal vaccin in eetbare delen van een plant wordt
gemaakt, kan het vaccin toegediend worden door simpelweg de plant of het eetbare
deel ervan op te eten. In dit proefschrift is het onderzoek naar de haalbaarheid van de
productie van orale vaccins in planten beschreven. Het onderzoek werd uitgevoerd in
muizen die oraal eiwitten toegediend kregen. Als eerste modeleiwit werd ovalbumine
(OVA) gebruikt en als tweede modeleiwit werd de B-subunit van het hittelabiele
enterotoxine van Escherichia coli gebruikt.
Wanneer een pathogeen een gastheer voor de eerste maal binnendringt wordt het
immuunsysteem geactiveerd. Bij deze primaire reactie slaat het geactiveerde
immuunsysteem herkenningspunten (epitopen) van het pathogeen op in het geheugen.
Bij een nieuwe besmetting met hetzelfde pathogeen herkent het immunologisch geheugen
van de gastheer dit pathogeen en wordt er sneller op de binnengedrongen
ziekteverwekker gereageerd (secundaire reactie). Een vaccin moet een pathogeen kunnen
nabootsen en het immuunsysteem dusdanig activeren dat het immuunsysteem in het
vervolg het pathogeen herkent. Het vaccin zelf  mag de gastheer niet ziek maken. Veel
vaccins bestaan uit volledige pathogenen die verzwakt of afgedood zijn. Hierbij bestaat
er echter altijd een mogelijk risico op reactivatie van het pathogeen. Daarom wordt er
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veel onderzoek gedaan naar veiliger geachte vaccins. Deze zouden kunnen bestaan uit
stukjes van het pathogeen, bijvoorbeeld alleen de voornaamste eiwitten van het pathogeen
die een immunologische reactie kunnen veroorzaken. Uit onderzoek is gebleken dat
vaccins die bestaan uit delen van het pathogeen minder effectief zijn dan vaccins die uit
het complete pathogeen bestaan en moeten daardoor aangevuld worden met een
adjuvant, een component die de immunologische reactie versterkt.
In hoofdstuk 1 werd een algemene inleiding over de achtergronden van orale vaccinatie
gegeven inclusief een beknopt overzicht van het mucosale immuunsysteem. In de
volgende twee hoofdstukken werd de optimalisatie van een immunisatie protocol voor
eetbare vaccins beschreven. De effectiviteit van een oraal vaccin bleek te kunnen worden
verhoogd door meerdere (multiple) doses van het vaccin te verstrekken. Wanneer deze
multiple doses niet meerdere dagen achtereen, maar om de dag werden gegeven, waren
er geen nadelige gevolgen voor de gezondheid (hoofdstuk 2). Orale vaccinatie bleek
minder effectief te zijn dan injecteerbare vaccinatie. Daarom werd er gekeken of de
twee vaccinatie vormen combineerbaar waren en zo bescherming in zowel het bloed
als in de mucosa opgewekt kon worden. Door het immuunsysteem eerst met een
injecteerbare (subcutane) vaccinatie optimaal te activeren (priming), was het mogelijk
om met behulp van orale vaccinaties het immuunsysteem te reactiveren (booster;
hoofdstuk 3). Bij deze experimenten werd OVA gebruikt als model eiwit en vloeibaar
rechtstreeks in de maag (intragastraal) van muizen toegediend. De resultaten van deze
studies hebben geleid tot een immunisatie protocol waarbij één enkele subcutane priming
met een antigen in combinatie met een adjuvant drie weken later wordt gevolgd door
orale boost immunisaties op  alternerende dagen (systemische priming/orale boost
protocol). Dit protocol werd toegepast op eetbare vaccins.
Als een model voor eetbare vaccins werd de B-subunit van het hittelabiele enterotoxine
(LTB) van Escherichia coli  geproduceerd in de knollen van transgene aardappelplanten.
Stukjes aardappelknol werden gevoerd aan muizen of een aardappelextract werd
intragastraal toegediend volgens het systemische priming/orale boost protocol. Specifieke
antilichamen tegen LTB waren meetbaar in zowel het bloed als in mucosale secreties
zoals de feces of  in darmschraapsels (hoofdstuk 4). Vervolgens werd bestudeerd of
LTB als adjuvant voor een ander, tegelijkertijd toegediend eiwit gebruikt kon worden.
Hiervoor werden transgene aardappelen gemaakt die, naast LTB, een eiwit (E2) van het
klassieke varkenspest virus tot expressie brachten. Dit eiwit werd samen met LTB in de
aardappelknollen geproduceerd (E2 + LTB), maar werd ook als fusie-eiwit aan LTB
geproduceerd (E2-LTB). De expressie niveaus van E2 + LTB en E2-LTB waren
aanzienlijk lager dan die van LTB alleen. Dit komt waarschijnlijk omdat E2 + LTB en
E2-LTB complexere en grotere moleculen zijn. Dit verklaart mogelijk ook waarom de
immunologische reactie tegen deze aardappelen veel lager was. Er werden alleen maar
specifieke antilichamen tegen LTB en niet tegen E2 gemeten. LTB geproduceerd in
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aardappelknollen kon niet dienen als adjuvant voor tegelijkertijd toegediende eiwitten
(hoofdstuk 5). Om de effectiviteit van op LTB gebaseerde vaccins te verhogen moeten
allereerst de expressieniveaus van de (fusie)eiwitten worden verhoogd.
Tijdens de experimenten met de aardappelknollen werd aangetoond dat er een verschil
bestaat tussen de immunologische reactie na het voeren van aardappelknollen en het
intragastraal toedienen van een aardappelextract. In hoofdstuk 6 werd dit uitgebreider
bestudeerd. Intragastrale toediening van OVA samen met een opgeloste voedselbrok
van muizen wekte sterkere immunologische reacties op dan het direct opeten van een
droge voedselbrok met vergelijkbare doses OVA. De route van orale toediening bleek
een belangrijke rol te spelen bij orale vaccinatie. Dit maakt experimenten met intragastrale
toediening van vaccins minder geschikt om de mogelijkheden van eetbare vaccins te
bepalen (hoofdstuk 6).
Het voorgestelde systemische priming/orale boost protocol bleek toepasbaar te zijn
voor intragastrale toediening van orale vaccins en het voeren van eetbare vaccins in het
bijzonder. Hoewel na het eten van rauwe knollen er niet-wenselijke bijwerkingen bij de
muizen zichtbaar waren. Het ideale door planten geproduceerde eetbare vaccin moet
het eiwit in voldoende mate tot expressie brengen, moet makkelijk te vermeerderen
zijn onder uiteenlopende omstandigheden en mag niet toxisch zijn wanneer het in hoge
doses wordt toegediend. Wanneer hiernaar gekeken wordt blijken aardappelen minder
geschikt te zijn. Consumptie van rauwe aardappelen is niet aan te raden en koken kan
het vaccin denatureren. Voor toekomstige studies naar eetbare vaccins moet een meer
geschikte plant gekozen worden (bijvoorbeeld tomaten- of bananenplanten).
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Tosca Lauterslager werd op 10 maart 1971 geboren te Oss. In deze stad heeft zij haar
lagere- en middelbare schooltijd doorgebracht. In 1990 werd aan het Maasland College
het atheneum-B diploma behaald en in datzelfde jaar werd de studie Biologie aan de
Katholieke Universiteit Nijmegen gestart. Ze volgde de studierichting Medische Biologie
met hoofdvakstages bij de sectie Medische Parasitologie (afdeling Medische
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Van  februari 1997 tot en met september 2001 was zij werkzaam als assistent in opleiding
bij de afdeling Virologie van de Universiteit Utrecht. Het onderzoek werd uitgevoerd
bij de divisie Dier en Omgeving van ID-Lelystad te Lelystad en staat beschreven in dit
proefschrift. Sinds november 2001 is zij als post-doc werkzaam de afdeling Pathologie
van het Vrije Universiteit Medisch Centrum te Amsterdam waar zij een bijdrage levert
aan het onderzoek naar het Epstein Barr virus.
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Dankwoord
Hè, hè, eindelijk ben ik aan dit laatste stuk van mijn proefschrift toe. Een zeer drukke
en, met name de laatste jaren, stressvolle tijd sluit ik hiermee af. Ik heb hierin geleerd dat
wetenschap zich niet helemaal in 4 jaar laat voorspellen en dat leuke resultaten vaak
moeizaam tot stand komen. Toch heeft dit mij er niet van weerhouden in het onderzoek
te blijven: de uitdagingen die ik hierin dagelijks ondervind, trekken mij nog steeds erg
aan. Alle jaren ben ik enorm gesteund door verschillende mensen, zowel binnen als
buiten het werk en ik doe een poging mijn dankbaarheid hier te verwoorden.
Allereerst wil ik mijn co-promotor Luuk bedanken. Ongeveer een jaar na mij kwam
je op het ID werken en vanaf het begin heb je veel interesse in mijn onderzoek getoond.
In van mijn derde jaar als AIO heb jij officieel de taak van co-promotor op je genomen.
En hoewel je ook toen al plannen had voor een eigen bedrijf, heb je altijd tijd voor mij
vrij gemaakt, ook toen ik al in Amsterdam begonnen. Je ongelofelijke enthousiasme is
een grote inspiratiebron voor mij geweest. Bedankt voor alles en succes met Covaccine!
Mijn begeleiders van het eerste uur, Wim en Michiel, wil ik bedanken voor hun, vaak
scherpe, kritiek waar ik echter heel veel van geleerd heb. Mijn promotoren Rob en Peter
wil ik bedanken voor de mogelijkheid die ze me gegeven hebben om bij hen te
promoveren en het feit dat ze altijd voor me klaar stonden als er weer eens wat geregeld
moest worden of  wanneer er weer een handtekening nodig was.
De overige leden van het eetbare vaccins-team mogen zeker ook niet onvermeld
blijven: Thijs, hartelijk bedankt voor de zeer prettige samenwerking (TNT) tijdens de
secties, de ELISAs en de overige proeven. Fijn dat je mijn paranimf  wilt zijn. Jan L.,
bedankt voor je steun door de jaren heen. Dirk, Jos, Mieke, Sofia en met name Dion:
hartelijk bedankt voor het maken van de aardappelen. Het was altijd leuk om in
Wageningen langs te komen. Dion, nog bedankt voor je hulp bij de twee aardappel-
stukken; we houden contact.
Natuurlijk wil ik mijn stagiaires niet vergeten: Rob, Nathaly en Hetty, jullie hebben
mij enorm geholpen door in de laatste twee jaren van mijn project, toen alles nog
moest gebeuren, gigantisch veel werk te verzetten. Voor een ELISA met meer dan 50
platen zullen wij nooit meer onze hand voor omdraaien!  Heel veel tijd is doorgebracht
in de stallen bij de muizen en (enkele keren) de konijnen. Hier heb ik altijd veel hulp
gehad van Jan, Henk, Johan, Arnold en Wilfred, die altijd voor mij klaarstonden als er
weer eens zo snel mogelijk, want we hebben nog maar weinig tijd een proef gestart
moest worden. Mijn bijna dagelijkse bezoek aan de stallen was hierdoor nooit onprettig.
Dan kom ik zo langzamerhand al aan bij de mensen die niet direct met mijn onderzoek
te maken hebben gehad, maar zonder wie mijn tijd in Lelystad heel anders zou zijn
geweest. Allereerst mijn andere paranimf, Conny: kamergenootje van het begin. Met
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elkaar hebben we veel lief en leed gedeeld en je hebt mijn jaartje als inwoonster van
Lelystad prettig veraangenaamd. Heel veel geluk voor jou, Joris en Anouk!
Marjorie, als overbuurvrouw op vleugel 15 hadden we vaak hele gesprekken en
veel steun aan elkaar als collega-AIOs bij moeizaam onderzoek. Heel veel succes met
het afronden van jouw boekje en veel geluk met je gezinnetje!
De overige (ex)-bewoners van vleugel 15: Fred, Johanna, Suzan, Petra, Jacob, Francis,
Annemarie, Maaike, Ditta, Jan-Willem, Bernie, Jan, Cor, Robin, Wil, Bereket en Anneke
(ook jij succes met Covaccine) en alle overige medewerkers van het oude IPE en de
latere divisie Dier en Omgeving: allen hartelijk bedankt voor de ontzettende gezellige
tijd die ik met jullie heb gehad! De (collega)-carpoolers wil ik bedanken voor het luisterend
oor tijdens de (lange) rit Wageningen-Lelystad v.v. Ik hoop dat de A30 snel klaar is.
Nu wordt het tijd om over te stappen naar mijn nieuwe werkgever, de afdeling
Pathologie bij het VUMC. Allereerst wil ik prof. Meijer bedanken voor de mogelijkheid
die hij me gegeven heeft om, naast mijn werk, mijn promotie af te ronden. Degene die
me daarbij het meest gesteund heeft is de grote EBV-baas zelf: Jaap, ontzettend bedankt
voor al je geduld als ik met mijn gedachten bij mijn promotie was, terwijl ik geacht
werd met EBV bezig te zijn. Ontzettend fijn dat je in mijn leescommissie hebt willen
plaatsnemen. Nu kan ik me eindelijk helemaal op het LMP1,2 werk storten!
De rest van de EBV-groep (Elisabeth, Jeffrey, Tabitha, Servi, Josine, Sandra, Tineke,
Sander en Wendy), mijn kamergenoten (Erik, Marco, Kirstin, Esther, Janneke en Duco),
de apoptose-groep (Saskia en Jettie), de polycomb-groep (Danny, Joost en Cindy),
mijn DC-raadgevers (Hetty en Tanja,) en de overige medewerkers van de afdeling
pathologie: bedankt voor al jullie belangstelling, luisterend oor en steun in het afgelopen
jaar. Rik, bedankt voor het plaatsnemen in de leescommissie.
Natuurlijk leef je niet alleen op het werk en gelukkig heb ik veel steun en belangstelling
ondervonden binnen mijn familie en vriendenkring. Allereerst: sorry dat ik de afgelopen
2 jaar niet altijd tijd en/of zin had om te bellen of om iets af te spreken. Nu het af is
heb ik ontzettend veel zin om te gaan resocialiseren met uitgebreide etentjes en spelletjes-
avonden.
Een speciale vermelding wil ik die unieke en (te?) gezellige sportclub geven: SKDO.
Zonder karate had ik het reizen nooit vol kunnen houden, kon ik mijn frustraties nooit
letterlijk van me afslaan en had ik nooit mijn man ontmoet. Al meer dan 15 jaar maakt
karate deel uit van mijn leven en het blijft een zeer belangrijke factor die mij aan Oss
bindt. Iedereen hartelijk bedankt (met name mijn trainingsmaatje!) voor alle belangstellende
vragen naar mijn onderzoek en naar mijn vorderingen tijdens het schrijven. Nu beland
ik onherroepelijk bij mijn familie die voor een (volgens sommigen te) groot deel
onlosmakelijk met deze club verbonden is.
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Mama en papa, hartelijk bedankt voor alle aanmoedigingen en vrijheden die jullie me
gegeven hebben toen ik besloot om biologie te gaan studeren. Nu heb ik weer tijd voor
jullie! Mario, ook jij hebt iets aan mijn Lelystadse-periode overgehouden: alle geluk
voor de toekomst voor jou en Mechteld (ex-collega!). Mijn schoonouders, zwagers en
schoonzussen wil ik bedanken voor alle oprechte belangstelling door de jaren heen, van
eerste-jaars studentje tot nu. Semi-zusje Senta en Geert en de rest van de familie wil ik
natuurlijk ook bedanken. Ondanks dat voor sommigen mijn onderzoek ver-van-het-
bed-gedoe was, kon ik bij iedereen mijn verhalen kwijt. Ontzettend bedankt!
Als allerlaatste nu zeker niet de minste: Rob, mijn tegenpool, steun, toeverlaat en,
bovenal, maatje. Hoewel ons werk en de daarbij behorende interesses zeer ver uit
elkaar liggen, heb je altijd veel belangstelling getoond in mijn onderzoek en voor zover
mogelijk me met zoveel mogelijk raad (drie is beter dan één) en daad (pipeteren op
zaterdagmiddag) bijgestaan. Je hebt er zelfs een jaar lang een weekendrelatie voor over
gehad. In mijn drukke leven met al mijn gereis en mijn onrustige, drukke karakter ben jij
een echt rustpunt in mijn leven. Het klinkt misschien cliché, maar het is echt waar:
zonder jou had ik het niet gered!
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